المؤلفون: L. A. Smirnova, A. M. Mitrofanova, N. N. Merkulov, M. V. Teleshova, D. G. Akhaladze, N. G. Uskova, A. P. Shapochnik, M. A. Rakov, A. A. Rumyantsev, I. V. Fisyun, D. L. Sakun, G. R. Kazaryan, A. P. Troitskaya, E. P. Erega, E. N. Bogatyreva, V. B. Makhonin, M. V. Borisova, I. V. Osipova, I. N. Skapenkov, N. S. Grachev, T. V. Shamanskaya, D. M. Konovalov, D. Yu. Kachanov, Л. А. Смирнова, А. М. Митрофанова, Н. Н. Меркулов, М. В. Телешова, Д. Г. Ахаладзе, Н. Г. Ускова, А. П. Шапочник, М. А. Раков, А. А. Румянцев, И. В. Фисюн, Д. Л. Сакун, Г. Р. Казарян, А. П. Троицкая, Е. П. Ерега, Е. Н. Богатырева, В. Б. Махонин, М. В. Борисова, И. В. Осипова, И. Н. Скапенков, Н. С. Грачёв, Т. В. Шаманская, Д. М. Коновалов, Д. Ю. Качанов

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 10, № 2 (2023); 11-27 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 10, № 2 (2023); 11-27 ; 2413-5496 ; 2311-1267

مصطلحات موضوعية: TFEB, children, adolescent, translocation renal cell carcinoma, TFE3, дети, подростки, транслокационный тип почечно-клеточной карциномы

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/930/820; Geller J.I., Dome J.S. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004;101(7):1575–83. doi:10.1002/cncr.20548.; Selle B., Furtwängler R., Graf N., Kaatsch P., Bruder E., Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980–2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer. 2006;107(12):2906–14. doi:10.1002/cncr.22346.; Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L., Bunin G.R. (eds.). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.; Znaor A., Lortet-Tieulent J., Laversanne M., Jemal A., Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67:519–30. doi:10.1016/j.eururo.2014.10.002.; Cajaiba M.M., Dyer L.M., Geller J.I., Jennings L.J., George D., Kirschmann D., Rohan S.M., Cost N.G., Khanna G., Mullen E.A., Dome J.S., Fernandez C.V., Perlman E.J. The classifi cation of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018;124(16):3381–9. doi:10.1002/cncr.31578.; Sagoyan G., Rubanskaya M., Kirgizov K., Strogonova A., Mitrofanova A., Rubansky M., Kerimov P., Suleymanova A., Temnyy A., Malakhova A., Kazantsev A., Varfolomeeva S. Renal cell carcinoma in children: single center experience. PV0169. 53th Congress of the International Society of Paediatric Oncology (SIOP), Virtual Congress, October 21–24, 2021. SIOP Abstracts. Pediatric Blood Cancer. 2021;68(S5):S234.; Kidney. In: Edge S.B., Byrd D.R., Compton C.C., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010. Pp. 479–89.; Moch H., Cubilla A.L., Humphrey P.A., Reuter V.E., Ulbright T.M. The 2016 WHO Classifi cation of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029.; van den Heuvel-Eibrink M.M., Hol J.A., Pritchard-Jones K., van Tinteren H., Furtwängler R., Verschuur A.C., Vujanic G.M., Leuschner I., Brok J., Rübe C., Smets A.M., Janssens G.O., Godzinski J., Ramírez-Villar G.L., de Camargo B., Segers H., Collini P., Gessler M., Bergeron C., Spreafi co F., Graf N.; International Society of Paediatric Oncology – Renal Tumour Study Group (SIOP– RTSG). Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14(12):743–52. doi:10.1038/nrurol.2017.163.; Vujanić G.M., Gessler M., Ooms A.H.A.G., Collini P., Coulombl’Hermine A., D’Hooghe E. Publisher Correction: The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2019;16(9):563. doi:10.1038/s41585-019-0191-5.; Nakata K., Colombet M., Stiller C.A., Pritchard-Jones K., Steliarova-Foucher E.; IICC-3 Contributors. Incidence of childhood renal tumours: An international population-based study. Int J Cancer. 2020;147(12):3313–27. doi:10.1002/ijc.33147.; Syed J.S., Nguyen K.A., Wu C.Q., Cost N.G., Siddiqui M.M., Hittelman A.B., Shuch B. Distinguishing pediatric and adolescent renal cell carcinoma from other renal malignancies. Pediatr Blood Cancer. 2017;64(5). doi:10.1002/pbc.26315.; van der Beek J.N., Geller J.I., de Krijger R.R., Graf N., Pritchard-Jones K., Drost J., Verschuur A.C., Murphy D., Ray S., Spreafi co F., Dzhuma K., Littooij A.S., Selle B., Tytgat G.A.M., van den Heuvel-Eibrink M.M. Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers (Basel). 2020;12(7):1776. doi:10.3390/cancers12071776.; Hsieh J.J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9.; Geller J.I., Cost N.G., Chi Y.Y., Tornwall B., Cajaiba M., Perlman E.J., Kim Y., Mullen E.A., Glick R.D., Khanna G., Daw N.C., Ehrlich P., Fernandez C.V., Dome J.S.; Children’s Oncology Group (COG) Renal Tumor Committee. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children’s Oncology Group AREN0321 study. Cancer. 2020;126(23):5156–64. doi:10.1002/cncr.33173.; Perlman E.J. Pediatric Renal Cell Carcinoma. Surg Pathol Clin. 2010;3(3):641–51. doi:10.1016/j.path.2010.06.011.; van der Beek J.N., Hol J.A., Coulomb-l’Hermine A., Graf N., van Tinteren H., Pritchard-Jones K., Houwing M.E., de Krijger R.R., Vujanic G.M., Dzhuma K., Schenk J.P., Littooij A.S., Ramírez-Villar G.L., Murphy D., Ray S., Al-Saadi R., Gessler M., Godzinski J., Ruebe C., Collini P., Verschuur A.C., Frisk T., Vokuhl C., Hulsbergen-van de Kaa C.A., de Camargo B., Sandstedt B., Selle B., Tytgat G.A.M., van den Heuvel-Eibrink M.M. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group. Int J Cancer. 2021;148(11):2724–35. doi:10.1002/ijc.33476.; Geller J.I., Ehrlich P.F., Cost N.G., Khanna G., Mullen E.A., Gratias E.J., Naranjo A., Dome J.S., Perlman E.J. Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children’s Oncology Group study AREN03B2. Cancer. 2015;121(14):2457–64. doi:10.1002/cncr.29368.; Jackson T.J., Williams R.D., Brok J., Chowdhury T., Ronghe M., Powis M., Pritchard-Jones K., Vujanić G.M.; Children’s Cancer and Leukaemia Group (CCLG) Renal Tumours Group. The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT 2001 trial. Pediatr Blood Cancer. 2019;66(6):e27627. doi:10.1002/pbc.27627.; Jackson T.J., Brisse H.J., Pritchard-Jones K., Nakata K., Morosi C., Oue T., Irtan S., Vujanic G., van den Heuvel-Eibrink M.M., Graf N., Chowdhury T.; SIOP RTSG Biopsy Working Group. How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group. Pediatr Blood Cancer. 2022;69(9):e29702. doi:10.1002/pbc.29702.; Saltzman A.F., Stokes W., Walker J., Cost N.G. Factors related to lymph node sampling at the time of surgery in children, adolescents, and young adults with unilateral non-metastatic renal cell carcinoma. J Pediatr Urol. 2019;15(3):259.e1–259.e7. doi:10.1016/j.jpurol.2019.01.009.; Saltzman A.F., Smith D.E., Gao D., Cost N.G. Lymph node yield in pediatric, adolescent and young adult Renal Cell Carcinoma – How many are enough? J Pediatr Surg. 2020;55(10):2030–4. doi:10.1016/j.jpedsurg.2020.04.004.; Hayakawa M., Hatano T., Tsuji A., Nakajima F., Ogawa Y. Patients with renal cysts associated with renal cell carcinoma and the clinical implications of cyst puncture: a study of 223 cases. Urology. 1996;47(5):643–6. doi:10.1016/s0090-4295(96)00016-7.; https://journal.nodgo.org/jour/article/view/930

الاتاحة: https://journal.nodgo.org/jour/article/view/930
https://doi.org/10.21682/2311-1267-2023-10-2-11-27

المؤلفون: D. G. Akhaladze, L. L. Rabaeva, A. A. Krivonosov, N. N. Merkulov, S. R. Talypov, I. V. Tverdov, N. G. Uskova, G. S. Rabaev, N. S. Grachev, Д. Г. Ахаладзе, Л. Л. Рабаева, А. А. Кривоносов, Н. Н. Меркулов, С. Р. Талыпов, И. В. Твердов, Н. Г. Ускова, Г. С. Рабаев, Н. С. Грачёв

المساهمون: The study was performed without external funding, Исследование проведено без спонсорской поддержки

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 9, № 4 (2022); 96-101 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 9, № 4 (2022); 96-101 ; 2413-5496 ; 2311-1267

مصطلحات موضوعية: дети, HIPEC, hyperthermic chemoperfusion, embryonal rhabdomyosarcoma, children, гипертермическая химиоперфузия, эмбриональная рабдомиосаркома

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/888/785; Institute USD of HAHSNC, US Department of Health and Human Services; National Cancer Institute. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. PsycEXTRA Dataset, 1999. doi:10.1037/e407432005-001.; Cecchetto G., Bisogno G., Treuner J., Ferrari A., Mattke A., Casanova M., Dall’Igna P., Zanetti I., Volpato S., Siracusa F., Scarzello G., Boglino C., Carli M. Role of surgery for nonmetastatic abdominal rhabdomyosarcomas: a report from the Italian and German Soft Tissue Cooperative Groups Studies. Cancer. 2003; 97:1974–80. doi:10.1002/cncr.11285.; Kazi M., Qureshi S. S. Primary Peritoneal Rhabdomyosarcomatosis in a 2-Year-Old Child Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy – Case Report and Review of Literature. Indian J Surg Oncol. 2021; 12: 322–6. doi:10.1007/s13193-021-01351-3.; Rodríguez-Ortiz L., Arjona-Sánchez A., Ibañez-Rubio M., Sánchez-Hidalgo J., Casado-Adam A., Rufi án-Peña S., Briceño-Delgado J. Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis. Surg Endosc. 2021; 35: 1778–85. doi:10.1007/s00464-020-07572-x.; Hayes-Jordan A., Green H., Lin H., Owusu-Agyemang P., Mejia R., Okhuysen-Cawley R., Cortes J., Fitzgerald N. E., McAleer M. F., Herzog C., Huh W. W., Anderson P. Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the fi rst 50 cases. Ann Surg Oncol. 2015; 22: 1726–32. doi:10.1245/s10434-014-4289-y.; Casey D. L., Wexler L. H., LaQuaglia M. P., Meyers P. A., Wolden S. L. Favorable outcomes after whole abdominopelvic radiation therapy for pediatric and young adult sarcoma. Pediatr Blood Cancer. 2014; 61: 1565–9. doi:10.1002/pbc.25088.; Kaseb H., Kuhn J., Babiker H. M. Rhabdomyosarcoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022. PMID: 29939543.; Lin C. N., Huang W. S., Huang T. H., Chen C. Y., Huang C. Y., Wang T. Y., Liao Y. S., Lee L. W. Adding Value of MRI over CT in Predicting Peritoneal Cancer Index and Completeness of Cytoreduction. Diagnostics (Basel). 2021; 11. doi:10.3390/diagnostics11040674.; Mercier F., Jeremie G., Alyami M., Delphine V., Vahan K., Pascal R., Sylvie I., Guillaume P., Olivier G. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Surg Endosc. 2020; 34: 4916–23. doi:10.1007/s00464-019-07280-1.; Arjona-Sanchez A., Esquivel J., Glehen O., Passot G., Turaga K. K., Labow D., Rufi an-Peña S., Morales R., van der Speeten K. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc. 2019; 33: 854–60. doi:10.1007/s00464-018-6352-4.; https://journal.nodgo.org/jour/article/view/888

الاتاحة: https://journal.nodgo.org/jour/article/view/888
https://doi.org/10.21682/2311-1267-2022-9-4-96-101

المؤلفون: Yu. N. Likar, D. G. Akhaladze, A. G. Rumyantsev, Ю. Н. Ликарь, Д. Г. Ахаладзе, А. Г. Румянцев

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 1 (2020); 62-69 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 1 (2020); 62-69 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-1

مصطلحات موضوعية: функция планируемого остатка печени, hepatobiliary scintigraphy, 99m Tc-mebrofenin, SPEC/CT, future remnant liver function, гепатобилиарная сцинтиграфия, 99m Tc-mebrofenin ( 99m Tc-Бромезида®), ОФЭКТ/КТ

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/575/536; Petrick J.L., Braunlin M., Laversanne M., Valery P.C., Bray F., McGlynn K.A. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer 2016;139(7):1534–45. doi.org/10.1002/ijc.30211.; Valery P.C., Laversanne M., Clark P.J., Petrick J.L., McGlynn K.A., Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67(2):600–11. doi:10.1002/hep.29498.; Howlader N., Noone A.M., Krapcho M., Miller D., Bishop K., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin K.A. (eds). SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. https://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.; van den Broek M.A., Olde Damink S.W., Dejong C.H., Lang H., Malago M., Jalan R., Saner F.H. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008;28(6):767–80. doi:10.1111/j.1478-3231.2008.01777.x.; Rahbari N.N., Garden O.J., Padbury R., Brooke-Smith M., Crawford M., Adam R., Koch M., Makuuchi M., Dematteo R.P., Christophi C., Banting S., Usatoff V., Nagino M., Maddern G., Hugh T.J., Vauthey J.N., Greig P., Rees M., Yokoyama Y., Fan S.T., Nimura Y., Figueras J., Capussotti L., Buchler M.W., Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149(5):713–24. doi:10.1016/j.surg.2010.10.001.; Kauffmann R., Fong Y. Post-hepatectomy liver failure. Hepatobiliary Surg Nutr 2014;3(5):238–46. doi:10.3978/j.issn.2304-3881.2014.09.01.; Abdalla E.K., Vauthey J.N. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg 2008;25(6):421–9. doi:10.1159/000184733.; Cucchetti A., Cescon M., Ercolani G., Di Gioia P., Peri E., Pinna A.D. Safety of hepatic resection in overweight and obese patients with cirrhosis. Br J Surg 2011;98(8):1147–54. doi.org/10.1002/bjs.7516.; Vetelainen R., van Vliet A., Gouma D.J., van Gulik T.M. Steatosis as a risk factor in liver surgery. Ann Surg 2007;245(1):20–30. doi:10.1097/01.sla.0000225113.88433.cf.; Agrawal S., Belghiti J. Oncologic resection for malignant tumors of the liver. Ann Surg 2011;253(4):656–65. doi:10.1097/SLA.0b013e3181fc08ca.; Jarnagin W.R., Gonen M., Fong Y., DeMatteo R.P., Ben-Porat L., Little S., Corvera C., Weber S., Blumgart L.H. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236(4):397–406; discussion 406–397. doi:10.1097/01.SLA.0000029003.66466.B3.; Kamath P.S., Kim W.R., Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology 2007;45(3):797–805. doi:10.1002/hep.21563.; Kokudo N., Vera D.R., Makuuchi M. Clinical application of TcGSA. Nucl Med Biol 2003;30(8):845–9. doi:10.1016/s0969-8051(03)00113-6.; Lau H., Man K., Fan S.T., Yu W.C., Lo C.M., Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997;84(9):1255–9. doi.org/10.1046/j.1365-2168.1997.02770.x.; Schneider P.D. Preoperative assessment of liver function. Surg Clin North Am 2004;84(2):355–73. doi:10.1016/S0039-6109(03)00224-X.; Schroeder R.A., Marroquin C.E., Bute B.P., Khuri S., Henderson W.G., Kuo P.C. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006;243(3):373–9. doi:10.1097/01.sla.0000201483.95911.08.; Clavien P.A., Emond J., Vauthey J.N., Belghiti J., Chari R.S., Strasberg S.M. Protection of the liver during hepatic surgery. J Gastrointest Surg 2004;8(3):313–27. doi:10.1016/j.gassur.2003.12.006.; Shoup M., Gonen M., D’Angelica M., Jarnagin W.R., DeMatteo R.P., Schwartz L.H., Tuorto S., Blumgart L.H., Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7(3):325–30. doi:10.1016/s1091-255x(02)00370-0.; Vauthey J.N., Chaoui A., Do K.A., Billimoria M.M., Fenstermacher M.J., Charnsangavei C., Hicks M., Alsfasser G., Lauwers G., Hawkins I.F., Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127(5):512–9. doi:10.1067/msy.2000.105294.; Cieslak K.P., Bennink R.J., de Graaf W., van Lienden K.P., Besselink M.G., Busch O.R., Gouma D.J., van Gulik T.M. Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford) 2016;18(9):773–80. doi:10.1016/j.hpb.2016.06.006.; Olthof P.B., Coelen R.J.S., Bennink R.J., Heger M., Lam M.F., Besselink V.G., Busch O.R., van Lienden K.P., van Gulik T.M. (99m)Tc-mebrofenin hepatobiliary scintigraphy predicts liver failure following major liver resection for perihilar cholangiocarcinoma. HPB (Oxford) 2017;19(10):850–8. doi:10.1016/j.hpb.2017.05.007.; Olthof P.B., Tomassini F., Huespe P.E., Truant S., Pruvot F.R., Troisi R.I., Castro C., Schadde E., Axelsson R., Sparellid E., Bennink R.J., Adam R., van Gulik T.M., de Santibanes E. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function. Surgery 2017;162(4):775–83. doi:10.1016/j.surg.2017.05.022.; Clavien P.A., Petrowsky H., DeOliveira M.L., Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356(15):1545–59. doi:10.1056/NEJMra065156.; Akaki S., Mitsumori A., Kanazawa S., Togami I., Takeda Y., Joja I., Hiraki Y. Technetium-99 m-DTPA-galactosyl human serum albumin liver scintigraphy evaluation of regional CT/MRI attenuation/signal intensity differences. J Nucl Med 1998;39(3):529–32. PMID: 9529304.; Marshall J.S., Green A.M., Pensky J., Williams S., Zinn A., Carlson D.M. Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. J Clin Invest 1974;54(3):555–62. doi:10.1172/JCI107792.; Nanashima A., Yamaguchi H., Shibasaki S., Morino S., Ide N., Takeshita H., Sawai T., Nakagoe T., Nagayasu T., Ogawa Y. Relationship between indocyanine green test and technetium- 99 m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: Clinical evaluation and patient outcome. Hepatol Res 2004;28(4):184–90. doi:10.1016/j.hepres.2003.11.010.; Iimuro Y. ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images. Visc Med 2017;33(6):449–54. doi:10.1159/000479046.; Sumiyoshi T., Okabayashi T., Negoro Y., Hata Y., Noda Y., Sui K., Iwata J., Mutsumoto M. (99m)Tc-GSA SPECT/CT fusion imaging for hepatectomy candidates with extremely deteriorated ICG value. Jpn J Radiol 2018;36(9):537–43. doi:10.1007/s11604-018-0753-0.; Fujioka H., Kawashita Y., Kamohara Y., Yamashita A., Mizoe A., Yamaguchi J., Azuma A., Furui J., Kanematsu T. Utility of technetium-99m-labeled-galactosyl human serum albumin scintigraphy for estimating the hepatic functional reserve. J Clin Gastroenterol 1999;28(4):329–33. doi:10.1097/00004836-199906000-00009.; Mimura T., Hamazaki K., Sakai H., Tanaka N., Mimura H. Evaluation of hepatic functional reserve in rats with obstructive jaundice by asyaloglycoprotein receptor. Hepatogastroenterology 2001;48(39):777–82. PMID: 11462923.; Beppu T., Hayashi H., Okabe H., Masuda T., Mima K., Otao R., Chikamoto A., Doi K., Ishiko T., Takamori H., Yoshida M., Shiraishi S., Yamashita Y., Baba H. Liver functional volumetry for portal vein embolization using a newly developed 99mTc-galactosyl human serum albumin scintigraphy SPECT-computed tomography fusion system. J Gastroenterol 2011;46(7):938–43. doi:10.1007/s00535-011-0406-x.; Hwang E.H., Taki J., Shuke N., Nakajima K., Kinuya S., Konishi S., Michigishi T., Aburano T., Tonami N. Preoperative assessment of residual hepatic functional reserve using 99 mTc-DTPA-galactosyl-human serum albumin dynamic SPECT. J Nucl Med 1999;40(10):1644–51. PMID: 10520704.; Satoh K., Yamamoto Y., Nishiyama Y., Wakabayashi H., Ohkawa M. 99 mTc-GSA liver dynamic SPECT for the preoperative assessment of hepatectomy. Ann Nucl Med 2003;17(1):61–7. doi:10.1007/bf02988261.; Hasegawa D., Onishi H. Evaluation of Accuracy for Quantitative Predictor of Hepatic Functional Reserve Using Planar and SPECT Images in the (99m)Tc-GSA Scintigraphy. Nihon Hoshasen Gijutsu Gakkai Zasshi 2017;73(10):1055–60. doi:10.6009/jjrt.2017_JSRT_73.10.1055.; Loberg M.D., Cooper M., Harvey E., Callery P., Faith W. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J Nucl Med 1976;17(7):633–8. PMID: 1271111.; Ghibellini G., Leslie E.M., Pollack G.M., Brouwer K.L. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 2008;25(8):1851–60. doi:10.1007/s11095-008-9597-0.; Krishnamurthy G.T., Krishnamurthy S. Cholescintigraphic measurement of liver function: how is it different from other methods? Eur J Nucl Med Mol Imaging 2006;33(10):1103–6. doi:10.1007/s00259-006-0182-7.; Leonard J.C., Hitch D.C., Manion C.V. The use of diethyl-IDA Tc 99 m clearance curves in the differentiation of biliary atresia from other forms of neonatal jaundice. Radiology 1982;142(3):773–6. doi:10.1148/radiology.142.3.7063701.; Gambhir S.S., Hawkins R.A., Huang S.C., Hall T.R., Busuttil R.W., Phelps M.E. Tracer kinetic modeling approaches for the quantification of hepatic function with technetium-99 m DISIDA and scintigraphy. J Nucl Med 1989;30(9):1507–18. PMID: 2769404.; Ekman M., Fjalling M., Friman S., Carlson S., Volkmann R. Liver uptake function measured by IODIDA clearance rate in liver transplant patients and healthy volunteers. Nucl Med Commun 1996;17(3):235–42. doi:10.1097/00006231-199603000-00011.; de Graaf W., van Lienden K.P., van Gulik T.M., Bennink R.J. (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J Nucl Med 2010;51(2):229–36. doi:10.2967/jnumed.109.069724.; Erdogan D., Heijnen B.H., Bennink R.J., Kok M., Dinant S., Straatsburg I.H., Gouma D.J., van Gulik T.M. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004;24(2):117–23. doi:10.1111/j.1478-3231.2004.00901.x.; Chapelle T., Op De Beeck B., Huyghe I., Francque S., Driessen A., Roeyen G., Ysebaert D., De Greef K. Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure? HPB (Oxford) 2016;18(6):494–503. doi:10.1016/j.hpb.2015.08.002.; Geisel D., Ludemann L., Froling V., Malinowski M., Stockmann M., Baron A., Gebauer B., Seehofer D., Prasad V., Denecke T. Imaging-based evaluation of liver function: comparison of (9)(9)mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol 2015;25(5):1384–91. doi:10.1007/s00330-014-3536-8.; Serenari M., Collaud C., Alvarez F.A., de Santibanes M., Giunta D., Pekoij J., Ardiles V., de Santibanes E. Interstage Assessment of Remnant Liver Function in ALPPS Using Hepatobiliary Scintigraphy: Prediction of Posthepatectomy Liver Failure and Introduction of the HIBA Index. Ann Surg 2018;267(6):1141–7. doi:10.1097/SLA.0000000000002150.; Mosteller R.D. Simplified calculation of body-surface area. N Engl J Med 1987;317(17):1098. doi:10.1056/NEJM198710223171717.; Rassam F., Olthof P.B., Richardson H., van Gulik T.M., Bennink R.J. Practical guidelines for the use of technetium-99m mebrofenin hepatobiliary scintigraphy in the quantitative assessment of liver function. Nucl Med Commun 2019;40(4):297–307. doi:10.1097/MNM.0000000000000973.; de Graaf W., van Lienden K.P., van den Esschert J.W., Bennink R.J., van Gulik T.M. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 2011;98(6):825–34. doi:10.1002/bjs.7456.; https://journal.nodgo.org/jour/article/view/575

الاتاحة: https://journal.nodgo.org/jour/article/view/575
https://doi.org/10.21682/2311-1267-2020-7-1-62-69

المؤلفون: E. I. Konopleva, D. V. Shevtsov, G. R. Kazaryan, A. M. Suleymanova, D. S. Abramov, D. G. Akhaladze, A. P. Shcherbakov, A. E. Druy, E. V. Kazaryan, T. V. Shamanskaya, D. Yu. Kachanov, S. R. Varfolomeeva, Е. И. Коноплева, Д. В. Шевцов, Г. Р. Казарян, А. М. Сулейманова, Д. С. Абрамов, Д. Г. Ахаладзе, А. П. Щербаков, А. Е. Друй, Э. В. Казарян, Т. В. Шаманская, Д. Ю. Качанов, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 3 (2020); 112-118 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 3 (2020); 112-118 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-3

مصطلحات موضوعية: эпителиальные опухоли тимуса, thymic carcinoma, thymic epithelial tumors, карцинома тимуса

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/634/580; Engels E.A. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5(10 suppl 4):260–5. doi:10.1097/JTO.0b013e3181f1f62d.; Ruffini E., Detterbeck F., Van Raemdonck D., Rocco G., Thomas P., Weder W., Brunelli A., Guererra F., Keshavjee S., Altorki N., Schutznerr J., Arame A., Spaggiari L., Lim E., Toker A., Venuta F. Thymic carcinoma: a cohort study of patients from the European Society of Thoracic Surgeons database. J Thorac Oncol 2014;9(4):541–8. doi:10.1097/JTO.0000000000000128.; Stachowicz-Stencel T., Orbach D., Brecht I., Schneider D., Bien E., Synakiewicz A., Rod J., Ferrari A., Cecchetto G., Bisogno G. Thymoma and Thymic Carcinoma in Children and Adolescents: A Report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015;51(16):2444–52. doi:10.1016/j.ejca.2015.06.121.; Sekihara K., Okuma Y., Kawamoto H., Hosomi Y. Clinical Outcome of Thymic Lymphoepithelioma-like Carcinoma: Case Report of a 14-Year-Old Male. Oncol Lett 2014;8(5):2183–6. doi:10.3892/ol.2014.2475.; Girard N., Ruffini E., Marx A., Faivre-Finn C., Peters S. Thymic Epithelial Tumours: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol 2015;26 Suppl 5:40–55. doi:10.1093/annonc/mdv277.; Travis W., Brambilla E., Burke A., Marx A., Nicholson A. WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press, 2015.; Rosai J., Sobin L. Histological Typing of Tumours of the Thymus. Springer, Berlin, Heidelberg, 1999.; Kojima Y., Ito H., Hasegawa S., Sasaki T., Inui K. Resected invasive thymoma with multiple endocrine neoplasia type 1. Jpn J Thorac Caridovasc Surg 2006;54(4):171–3. doi:10.1007/BF02662474.; Hsueh C., Kue T., Tsang N., Wu Y., Yang C., Hung I. Thymic Lymphoepitheliomalike Carcinoma in Children: Clinicopathologic Features and Molecular Analysis. J Pediatr Hematol Oncol 2006;28(12):785–90. doi:10.1097/MPH.0b013e31802d3a83.; Evoli A., Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol 2014;9(9):143–7. doi:10.1097/JTO.0000000000000300.; Chen G., Marx A., Wen-Hu C., Yong J., Puppe B., Stroebel P., MuellerHermlink H. New WHO histologic classifıcation predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95(2):420–9. doi:10.1002/cncr.10665.; Kondo K., Monden Y. Therapy for Thymic Epithelial Tumors: A Clinical Study of 1,320 Patients from Japan. Ann Thorac Surg 2003;76(3):878–84. https://doi.org/10.1016/S0003-4975(03)00555-1.; Stachowicz-Stencel T., Bien E., Balcerska A., Godzinski J., Synakiewicz A., Madziara W., Perek-Polnik M., Peregud-Pogorzelski J., Pietras W., Pobudejska A., Kurylak A., Mankowski P. Thymic carcinoma in children: a report from the Polish Pediatric Rare Tumors Study. Pediatr Blood Cancer 2010;54(7):916–20. doi:10.1002/pbc.22482.; Carretto E., Inserra A., Ferrari A., Conte M., Di Cataldo A., Migliorati R., Cecchetto G., Bisogno G. Epithelial thymic tumours in paediatric age: a report from the TREP project. Orphanet J Rare Dis 2011;5(21):6–28. doi:10.1186/1750-1172-6-28.; Litvak A., Woo K., Hayes S., Huang J., Rimner A., Sima C., Moreira A., Tsukazan M., Riely G. Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging. J Thorac Oncol 2014;9(12):1810–5. doi:10.1097/JTO.0000000000000363.; National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Thymomas and Thymic Carcinomas 2.2019. 2019 Mar 11. National Comprehensive Cancer Network. Abstract available at https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf.; Lemma G., Lee J., Aisner S., Langer C., Tester W., Johnson D., Loehrer P. Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma. J Clin Oncol 2011;29(15):2060–5. doi:10.1200/JCO.2010.32.9607.; Hirai F., Yamanaka T., Taguchi T., Daga H., Ono A., Tanaka K., Kogure Y., Shimizu J., Kimura T., Fukuoka J., Iwamoto Y., Sasaki H., Takeda K., Seto T., Ichinose Y., Nakagawa K., Nakanishi Y. A Multicenter Phase II Study of Carboplatin and Paclitaxel for Advanced Thymic Carcinoma: WJOG4207L. Ann Oncol 2015;26(2):363–8. doi:10.1093/annonc/mdu541.; Petrini I., Zucali P., Lee H., Pineda M., Meltzer P., Walter-Rodriguez B., Roncalli M., Santoro A., Wang Y, Giaccone G. Expression and mutational status of c-Kit in thymic epithelial tumors. J Thorac Oncol 2010;5(9):1447–53 doi:10.1097/JTO.0b013e3181e96e30.; Thomas A., Rajan A., Berman A., Tomita Y., Brzezniak C., Lee M., Lee S., Ling A., Spittler A., Carter C., Guha U., Wang Y., Szabo E., Meltzer P., Steinberg S., Trepel J., Loehrer P., Giaccone G. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16(2):177–86. doi:10.1016/S1470-2045(14)71181-7.; Giaccone G., Kim C., Thompson J., McGuire C., Kallakury B., Chahine J., Manning M., Mogg R., Blumenschein W., Tan M., Subramaniam D., Liu S., Kaplan I., McCutcheon J. Articles Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19(3):347–55. doi:10.1016/S1470-2045(18)30062-7.; https://journal.nodgo.org/jour/article/view/634

الاتاحة: https://journal.nodgo.org/jour/article/view/634
https://doi.org/10.21682/2311-1267-2020-7-3-112-118

المؤلفون: D. G. Akhaladze, N. G. Uskova, G. S. Rabaev, D. Yu. Kachanov, M. V. Teleshova, R. A. Moiseenko, N. S. Grachev, S. R. Varfolomeeva, Д. Г. Ахаладзе, Н. Г. Ускова, Г. С. Рабаев, Д. Ю. Качанов, М. В. Телешова, Р. А. Моисеенко, Н. С. Грачёв, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 6, № 4 (2019); 12-18 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 6, № 4 (2019); 12-18 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2019-6-4

مصطلحات موضوعية: детская онкология, ALPPS, two staged hepatectomy, children, pediatric oncology, двухэтапная резекция печени, дети

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/548/510; Baumgart J., Lang S., Lang H. A new method for induction of liver hypertrophy prior to right trisectionectomy: a report of three cases. HPB (Oxford) 2011;13(suppl 2):71-2. doi: 10.nn/j.1477-2574.20U.00308.x.; de Santibanes E., Clavien P.A. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg 2012;255(3):415-7. doi:10.1097/SLA.0b013e318248577d.; Schnitzbauer A.A., Lang S.A., Goessmann H., Nadalin S., Baumgart J., Farkas S.A., Fichtner-Feigl S., Lorf T., Goralcyk A., Horbelt R., Kroemer A., Loss M., Rummele P., Scherer M.N., Padberg W., Konigsrainer A., Lang H., Obed A., Schlitt H.J. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012;255(3):405-14. doi:10.1097/SLA.0b013e31824856f5.; de Santibanes E., Alvarez F.A., Ardiles V. How to avoid postoperative liver failure: a novel method. World J Surg 2012;36(1):125-8. doi: 10.m07/s00268-0U-1331-0.; Robles R., Parrilla P., Lopez-Conesa A., Brusadin R., de la Pena J., Fuster M., Garda-Lopez J.A., Hernandez E. Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure. Br J Surg 2014;101(9): 1129—34. doi:10.1002/bjs.9547.; Li J., Kantas A., Ittrich H., Koops A., Achilles E.G., Fischer L., Nashan B. Avoid “All-Touch” by Hybrid ALPPS to achieve oncological efficacy. Ann Surg 2016;263(1):e6-7. doi:10.1097/SLA.0000000000000845.; Petrowsky H., Gyori G., de Oliveira M., Lesurtel M., Clavien P.A. Is partial-ALPPS safer than ALPPS? A single-center experience. Ann Surg 2015;261(4):e90-2. doi: 10.m97/SLA.0000000000001087.; Machado M.A., Makdissi F.F., Surjan R.C. Totally laparoscopic ALPPS is feasible and may be worthwhile. Ann Surg 2012;256(3):e13; author reply: e16-9. doi:10.1097/SLA.0b013e318265ff2e.; Conrad C., Shivathirthan N., Camerlo A., Strauss C., Gayet B. Laparoscopic portal vein ligation with in situ liver split for failed portal vein embolization. Ann Surg 2012;256(3):e14-5; author reply: e16-7. doi:10.1097/SLA.0b013e318265ff44.; Vicente E., Quijano Y., Ielpo B., Fabra I. First ALPPS procedure using a total robotic approach. Surg Oncol 2016;25(4):457. doi: m.m16/j.suronc.2015.m.001.; Cai Y.L., Song P.P., Tang W., Cheng N.S. An updated systematic review of the evolution of ALPPS and evaluation of its advantages and disadvantages in accordance with current evidence. Medicine (Baltimore) 2016;95(24):e3941. doi:10.1097/MD.0000000000003941.; Chan A., Chung P.H.Y., Poon R.T.P. Little girl who conquered the “ALPPS”. World J Gastroenterol 2014;20(29):10208-11. doi: http://dx.doi.org/10.3748/wjg.v20.i29.10208.; Zsiros J., Brugieres L., Brock P., Roebuck D., Maibach R., Zimmermann A., Childs M., Pariente D., Laithier V., Otte J.B., Branchereau S., Aronson D., Rangaswami A., Ronghe M., Casanova M., Sullivan M., Morland B., Czauderna P., Perilongo G.; International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 2013;14(9):834-42. doi:10.1016/S1470-2045(13)70272-9.; Moisan F., Gayet B., Ward M.A., Tabchouri N., Fuks D. Segment 7 Laparoscopic Liver Resection: Is It Possible to Resect When Metastatic Lesions Border Suprahepatic Veins? J Gastrointest Surg 2018;22(9):1643-4. doi:10.1007/s11605-018-3824-8.; Abu Hilal M., Aldrighetti L., Dagher I., Edwin B., Troisi R.I., Alikhanov R., Aroori S., Belli G., Besselink M., Briceno J., Gayet B., D’Hondt M., Lesurtel M., Menon K., Lodge P., Rotellar F., Santoyo J., Scatton O., Soubrane O., Sutcliffe R., Van Dam R., White S., Halls M.C., Cipriani F., Van der Poel M., Ciria R., Barkhatov L., Gomez-Luque Y., Ocana-Garcia S., Cook A., Buell J., Clavien P.A., Dervenis C., Fusai G., Geller D., Lang H., Primrose J., Taylor M., Van Gulik T., Wakabayashi G., Asbun H., Cherqui D. The Southampton Consensus Guidelines for Laparoscopic Liver Surgery. Ann Surg 2018;268(1):11-8. doi:10.1097/SLA.0000000000002524.; Hong J.C., Kim J., Browning M., Wagner A., Lerret S., Segura A.D., Zimmerman M.A. Modified Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Hepatoblastoma in a Small Infant. Ann Surg 2017;266(2):e16-7. doi:10.1097/SLA.0000000000002217.; Wiederkehr J.C., Avilla S.G., Mattos E., Coelho I.M., Ledesma J.A., Concei9ao A.F., Wiederkehr H.A., Wiederkehr B.A. Associating liver partition with portal vein ligation and staged hepatectomy (ALPPS) for the treatment of liver tumors in children. J Pediatr Surg 2015;50(7):1227-31. doi:10.1016/jjpedsurg.2014.10.019.; Qazi A.Q., Syed A.A., Khan A.W., Hanif F. Early multifocal recurrence of hepatoblastoma in the residual liver after R0 liver resection with ALPPS procedure: a case report. Ann Transl Med 2016;4(19):375. doi: 10.2m37/atm.2016.10.01.; Xu Z.L., Wang L., Fan W., Hao Z.H., Li C. ALPPS for hepatic mesenchymal hamartoma in an infant. J Pediatr Surg Case Rep 2018;37:70-3. doi:10.1016/j.epsc.2018.07.023.; Ким Э.Ф., Филин А.В., Семенков А.В., Ушакова И.А., Бурмистров Д.С., Метелин А.В., Ховрин В.В., Крыжановская Е.Ю., Марченко А.Л., Варфоломеева С.Р., Качанов Д.Ю., Моисеенко Р.А., Ускова Н.Г Двухэтапная обширная резекция печени при гепатобластоме: первый отечественный опыт. Клиническая и экспериментальная хирургия. Журнал имени академика Б.В. Петровского 2013;2:28-35.; Сидоров Д.В., Рябов А.Б., Врублевский С.Г, Трунов В.О., Ложкин М.В., Глазунов А.А., Горохов Д.В., Мордвин П.А., Ма-нукян С.Р., Гурзо Ю.Д. Двухэтапная резекция печени (ALLPS) у ребенка с гигантской эмбриональной саркомой. Детская хирургия 2017;21(1):47-50. doi: 10/18821/1560-9510-2017-21-1-47-50.; https://journal.nodgo.org/jour/article/view/548

الاتاحة: https://journal.nodgo.org/jour/article/view/548
https://doi.org/10.21682/2311-1267-2019-6-4-12-18

المؤلفون: L. A. Smirnova, D. Yu. Kachanov, A. P. Shcherbakov, D. G. Akhaladze, M. V. Teleshova, Yu. N. Likar, T. V. Shamanskaya, Л. А. Смирнова, Д. Ю. Качанов, А. П. Щербаков, Д. Г. Ахаладзе, М. В. Телешова, Ю. Р. Ликарь, Т. В. Шаманская

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 3 (2020); 125-131 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 3 (2020); 125-131 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-3

مصطلحات موضوعية: сцинтиграфия с 123I-метайодбензилгуанидином, children, stage 4S, observation group, metastases, computed tomography, scintigraphy with, 4S стадия, дети, группа наблюдения, метастазы, компьютерная томография

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/636/582; Шаманская Т.В., Качанов Д.Ю., Феоктистова Е.В., Терещенко Г.В., Ликарь Ю.Н., Муфтахова Г.М., Талыпов С.Р., Варфоломеева С.Р. Гетерогенность 4S стадии нейробластомы: мультидисциплинарный взгляд. Российский журнал детской гематологии и онкологии 2017;4(1):83–8. doi:10.17650/2311-1267-2017-4-1-83-88.; Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castleberry R.P., Bernardi B.D., Evans A. E., Favrot M.C., Hedborg F., Kaneko M., Kemshead J., Lampert F., Lee R.J., Look A.T., Pearson A.D., Philip T., Roald B., Sawada T., Seeger R.C., Tsuchida Y., Voute P.A. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466–77. doi:10.1200/JCO.1993.11.8.1466.; Pritchard J., Hickman J.A. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994;344(8926):869–70. doi:10.1016/S0140-6736(94)92834-7.; van Noesel M.M., Hählen K., Hakvoort-Cammel F.G., Egeler R.M. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer 1997;80(5):834–43. PMID: 9307181.; Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., Kaneko M., London W.B., Matthay K.K., Nuchtern J.G., von Schweinitz D., Simon T., Cohn S.L., Pearson A.D.J.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298–303. doi:10.1200/JCO.2008.16.6876.; Pepper W.A. A study of congenital sarcoma of the liver and suprarenal with report of a case. Am J Med Sci 1901;121(3):287.; Rothenberg A.B., Berdon W.E., D’Angio G.J., Yamashiro D.J., Cowles R.A. Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 2009;39(2):155–60. doi:10.1007/s00247-008-1062-z.; Качанов Д.Ю., Шаманская Т.В., Муфтахова Г.М., Варфоломеева С.Р. Нейробластома 4S стадии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2014;13(2):9–19.; Hero B., Simon T., Horz S., Berthold F. Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis? Med Pediatr Oncol 2000;35:683–7. doi:10.1002/1096-911x(20001201)35:63.0.co;2-f.; Simon T., Hero B., Schulte J.H., Deubzer H., Hundsdoerfer P., von Schweinitz D., Fuchs J., Schmidt M., Prasad V., Krug B., Timmermann B., Leuschner I., Fischer M., Langer T., Astrahantseff K., Berthold F., Lode H., Eggert A. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klin Pädiatr 2017;229(3):147–67. doi:10.1055/s-0043-103086.; Simon T., Hero B., Berthold F. Testicular and paratesticular involvement by metastatic neuroblastoma. Cancer 2000;88(11):2636–41. doi:10.1002/1097-0142(20000601)88:113.0.CO;2-K.; Moser O., Scheurlen W., Leipold A., Dilloo D., Hero B. Muscle involvement in neuroblastoma with spontaneous regression. Proceedings of Advances in Neuroblastoma Research Congress. 13–16 May 2014. Cologne, Germany. Abstr. POC024. Pp. 237–238.; Meyers P.A., Heller G., Healey J.H., Huvos A., Applewhite A., Sun M., LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11(3):449–53. doi:10.1200/jco.1993.11.3.449.; Жилкин И.В., Ахаладзе Д.Г., Литвинов Д.В., Ускова Н.Г., Тихонова М.В., Грачев Н.С., Карачунский А.И. Метастатическое поражение легких при остеосаркоме. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2019;18(4):127–35. doi:10.24287/1726-1708-2019-18-4-127-135.; Bosma S.E., Rueten‐Budde A.J., Lancia C., Ranft A., Dirksen U., Krol A.D., Gelderblom H., van de Sande M., Dijkstra P., Fiocco M. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model for Ewing sarcoma. Pediatr Blood Cancer 2019;66(11):e27943. doi:10.1002/pbc.27943.; https://journal.nodgo.org/jour/article/view/636

الاتاحة: https://journal.nodgo.org/jour/article/view/636
https://doi.org/10.21682/2311-1267-2020-7-3-125-131

المؤلفون: G. B. Sagoyan, M. Sh. Shingarova, T. V. Shamanskaya, D. G. Akhaladze, N. N. Merkulov, R. A. Moiseenko, N. G. Uskova, V. Yu. Roshchin, E. S. Ternovaya, A. N. Novikov, I. V. Fisyun, D. Yu. Kachanov, S. R. Varfolomeeva, Г. Б. Сагоян, М. Ш. Шингарова, Т. В. Шаманская, Д. Г. Ахаладзе, Н. Н. Меркулов, Р. А. Моисеенко, Н. Г. Ускова, В. Ю. Рощин, Е. С. Терновая, А. Н. Новиков, И. В. Фисюн, Д. Ю. Качанов, С. Р. Варфоломеева

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 105-112 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 105-112 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4

مصطلحات موضوعية: паранеопластический синдром, children, secretory diarrhea, vasoactive intestinal peptide, paraneoplastic syndrome, дети, секреторная диарея, вазоактивный интестинальный пептид

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/450/432; Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202–11. doi:10.1056/NEJMra0804577.; Goodman M.S., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L. Jr, Bunin G.R., eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975– 1995. National Cancer Institute, SEER Program. Bethesda, MD, 1999. Pp. 65–72.; Spix C., Pastore G., Sankila R., Stiller C.A., Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978– 1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi:10.1016/j.ejca.2006.05.008.; Геворков А.Р. Паранеопластические синдромы. В кн.: Онкология: национальное руководство. Под ред. В.И. Чиссова, М.И. Давыдова. М.: ГЭОТАР-Медиа, 2008. С. 547–570. [Gevorkov A.R. Paraneoplastic syndromes. In: Oncology: National guidelines. Edited by V.I. Chissov, M.I. Davydov. M.: GEOTAR-Media, 2008. Pp. 547–570. (In Russ.)].; Качанов Д.Ю., Шаманская Т.В., Малевич О.Б., Варфоломеева С.Р. Синдром опсоклонус-миоклонус и нейробластома (обзор литературы). Российский журнал детской гематологии и онкологии 2014;1(1):62–9. doi:10.17650/2311-1267-2014-0-1-62-69. [Kachanov D.Yu., Shamanskaya T.V., Malevich O.B., Varfolomeeva S.R. Opsoclonusmyoclonus syndrome and neuroblastoma (a review of literature). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2014;1(1):62–9. doi:10.17650/2311-1267-2014-0-1-62-69. (In Russ.)].; Qureshi S.S., Bhagat M., Anam J., Vora T. Aggressive cervical neuroblastoma with a rare paraneoplastic syndrome: A therapeutic dilemma. J Indian Assoc Pediatr Surg 2016;21(4):181–3. doi:10.4103/0971-9261.186548.; Bourdeaut F., de Carli E., Timsit S., Coze C., Chastagner P., Sarnacki S., Delattre O., Peuchmaur M., Rubie H., Michon J.; Neuroblastoma Committee of the Société Française des Cancers et Leucémies de l’Enfant et de l’Adolescent. VIP Hypersecretion as Primary or Secondary Syndrome in Neuroblastoma: A Retrospective Study by the Société Française des Cancers de l’Enfant (SFCE). Pediatr Blood Cancer 2009;52(5):585–90. doi:10.1002/pbc.21912.; Farthing M., Salam M., Lindberg G., Dite P., Khalif I., Salazar-Lindo E., Ramakrishna B.S., Goh K., Thomson A., Khan A.G., Krabshuis J., LeMair A. Acute diarrhea in adults and children: a global perspective. World Gastroenterology Organisation Global Guidelines, 2012. [Electronic resource]: http://www. worldgastroenterology.org/UserFiles/fi le/guidelines/acute-diarrheaenglish-2012.pdf (appeal date 20.09.2018).; Verner J.V., Morrison A.B. Islet cell tumor and a syndrome of refractory watery diarrhoea and hypokalemia. Am J Med 1958;25:374–80. PMID: 13571250.; Green M., Cooke R.E., Lattanzi W. Occurrence of chronic diarrhea in three patients with ganglioneuromas. Pediatrics 1959;23(5):951–5. PMID: 13645132.; Balemba O.B., Grondahl M.L., Mbassa G.K., Semuguruka W.D., HaySmith A., Skadhauge E., Dantzer V. The organization of the enteric nervous system in the submucous and mucous layers of the small intestine of the pig studied by VIP and neurofi lament protein immunohistochemistry. J Anat 1998;192(Pt 2):257–67. doi:10.1046/j.1469-7580.1998.19220257.x.; Pincus D.W., DiCicco-Bloom E.M., Black I.B. Vasoactive intestinal peptide regulates mitosis, diff erentiation and survival of cultured sympathetic neuroblasts. Nature 1990;343(6258):564–7. doi:10.1038/343564a0.; Tiedemann K., Long R.G., Pritchard J., Bloom S.R. Plasma vasoactive intestinal polypeptide and other regulatory peptides in children with neurogenic tumours. Eur J Pediatr 1981;137(2):147–50. PMID: 7308225.; Tiedemann K., Pritchard J., Long R., Bloom S.R. Intractable diarrhea in a patient with vasoactive intestinal peptide-secreting neuroblastoma. Attempted control by somatostatin. Eur J Pediatr 1981;137(2):217–9. PMID: 6118274.; Adam N., Lim S.S., Ananda V., Chan S.P. VIPoma syndrome: challenges in management. Singapore Med J 2010;51(7):e129–32. PMID: 20730389.; Kabalan P., Giff ord A.J., Ziegler D.S. Unresectable VIP-secreting neuroblastoma: Effi cacy of debulking and steroids for symptom control. Pediatr Blood Cancer 2018;65(12):e27358. doi:10.1002/pbc.27358.; https://journal.nodgo.org/jour/article/view/450

الاتاحة: https://journal.nodgo.org/jour/article/view/450
https://doi.org/10.17650/2311-1267-2018-5-4-105-112

المؤلفون: O. M. Tsiroulnikova, I. V. Zhilkin, D. G. Akhaladze, О. М. Цирульникова, И. В. Жилкин, Д. Г. Ахаладзе

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 18, № 1 (2016); 67-77 ; Вестник трансплантологии и искусственных органов; Том 18, № 1 (2016); 67-77 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2016-1

مصطلحات موضوعية: профилактика цитомегаловирусной инфекции, cytomegalovirus infection, antiviral prophylaxis, preemptive therapy, antiviral therapy, цитомегаловирусная инфекция

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/621/529; Готье СВ, Константинов БА, Цирульникова ОМ. Трансплантация печени. М.: МИА, 2008. Gautier SV, Konstantinov BA, Tsirulnikova OM. Transplantatsiya pecheni. M.: MIA, 2008.; Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep. 2012; 14 (6): 633–641. doi:10.1007/s11908-012-0292-2.; Fishman J, Emery V, Freeman R et al. Cytomegalovirus in transplantation – Challenging the status quo. Clin Transplant. 2007; 21 (2): 149–158. doi:10.1111/j.1399-0012.2006.00618.x.; Shepherd RW, Turmelle Y, Nadler M et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant. 2008; 8 (2): 396–403. doi:10.1111/j.1600-6143.2007.02068.x.; Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein–Barr virus infections. Herpes. 2003; 10 (3): 60–65. http://europepmc.org/abstract/med/14759337. Accessed November 25, 2015.; Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27–29 February 2004. Herpes. 2004; 11 (3): 77–86. http://www.ncbi.nlm.nih.gov/pubmed/15960905. Accessed November 25, 2015.; Цирульникова ОМ, Цирульникова ИЕ. Инфекции в трансплантологии; под ред. С.В. Готье. 2009; 223–246. Tsirulnikova OM, Tsirulnikova IE. Infekcii v transplantologii; pod red. Gautier S.V. 2009; 223–246.; Bowman JS, Green M, Scantlebury VP et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant. 1991; 5 (4): 294–300. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3002137&tool=pmcentrez&rendertype=abstract. Accessed November 26, 2015.; Kawano Y, Mizuta K, Sanada Y et al. Risk Factors of Cytomegalovirus Infection After Pediatric Liver Transplantation. Transplant Proc. 2014; 46 (10): 3543–3547. doi:10.1016/j.transproceed.2014.09.150.; Indolfi G, Heaton N, Smith M, Mieli-Vergani G, Zuckerman M. Effect of early EBV and/or CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation. Clin Transpl. 2012; 26 (1): E55–E61. doi:10.1111/j.1399-0012.2011.01535.x.; Jain A, Orloff M, Kashyap R et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc. 2005; 37 (7): 3182–3186. doi:10.1016/j.transproceed.2005.07.032.; Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation. 2005; 79 (10): 1428–1434. http://www.ncbi.nlm.nih.gov/pubmed/15912115. Accessed November 26, 2015.; Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl. 2007; 13 (12): 1703–1709. doi:10.1002/lt.21280.; Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of effi cacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet. 1997; 350 (9093): 1729–1733. doi:10.1016/S0140-6736(97)05535-9.; Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4 (4): 611–620. doi:10.1111/j.1600-6143.2004.00382.x.; Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation – challenging the status quo. Clin Transplant. 21 (2): 149–158. doi:10.1111/j.1399-0012.2006.00618.x.; Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998; 338 (24): 1741–1751. doi:10.1056/NEJM199806113382407.; Ljungman P, Griffi ths P, Paya C. Defi nitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002; 34 (8): 1094–1097. doi:10.1086/339329.; Kelly DA, Bucuvalas JC, Alonso EM et al. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013; 19 (8): 798–825. doi:10.1002/lt.23697.; Fica A, Cervera C, Pérez N et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis. 2007; 9 (3): 203–210. doi:10.1111/j.1399-3062.2007.00220.x.; Squires JE, Sisk RA, Balistreri WF, Kohli R. Isolated unilateral cytomegalovirus retinitis: a rare long-term complication after pediatric liver transplantation. Pediatr Transplant. 2013; 17 (1): E16–E19. doi:10.1111/j.1399-3046.2012.01752.x.; Gotthardt DN, Senft J, Sauer P et al. Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transpl. 2013; 19 (10): 1142–1150. doi:10.1002/lt.23713.; Hoppe L, Marroni CA, Bressane R et al. Impact of cytomegalovirus infection on long-term survival after orthotopic liver transplantation. Transplant Proc. 2006; 38 (6): 1924–1925. doi:10.1016/j.transproceed.2006.06.074.; Sun H-Y, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant. 2008; 8 (10): 2111–2118. doi:10.1111/j.1600-6143.2008.02369.x.; Kullberg-Lindh C, Ascher H, Krantz M, Lindh M. Quantitative analysis of CMV DNA in children the fi rst year after liver transplantation. Pediatr Transplant. 2003; 7 (4): 296–301. doi:10.1034/j.1399-3046.2003.00086.x.; Kanj SS, Sharara AI, Clavien P-A, Hamilton JD. Cytomegalovirus Infection Following Liver Transplantation: Review of the Literature. Clin Infect Dis. 1996; 22 (3): 537–549. doi:10.1093/clinids/22.3.537.; Madan RP, Campbell AL, Shust GF et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation. 2009; 87 (9): 1318–1324. doi:10.1097/TP.0b013e3181a19cda.; John LR. Forsythe. Transplantation. Elsevier Science; 2013.; Falagas ME, Arbo M, Ruthazer R et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation. 1997; 63 (11): 1595–1601. http://www.ncbi.nlm.nih.gov/pubmed/9197352. Accessed November 25, 2015.; Hardinger KL, Schnitzler MA, Brennan DC. Cytomegalovirus increases the rate of graft loss after liver transplantation. Am J Transpl. 2003; 5: 523.; Gupta P, Hart J, Cronin D, Kelly S, Millis JM, Brady L. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation. 2001; 72 (6): 1098–1102. http://www.ncbi.nlm.nih.gov/pubmed/11579307. Accessed November 26, 2015.; Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wight DG, Alexander GJ. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation. 2000; 69 (1): 30–35. http://www.ncbi.nlm.nih.gov/pubmed/10653376. Accessed November 26, 2015.; Rubin RH. Importance of CMV in the transplant population. Transpl Infect Dis. 1999; 1 (Suppl. 1): 3–7. http://europepmc.org/abstract/med/11565584. Accessed November 26, 2015.; Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis. 1999; 1 (Suppl. 1): 8–12. http://europepmc.org/abstract/med/11565588. Accessed November 26, 2015.; Milan A, Sampaio AM, Guardia AC et al. Identifi cation of Bacterial Infections and Clinical Manifestation Associated With Cytomegalovirus in Liver Transplantation Patients. Transplant Proc. 2013; 45 (3): 1130–1132. doi:10.1016/j.transproceed.2013.02.016.; Harkins L, Volk AL, Samanta M et al. Specifi c localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet (London, England). 2002; 360 (9345): 1557–1563. doi:10.1016/S0140- 6736(02)11524-8.; Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003; 170 (3): 998–1002. doi:10.1097/01.ju.0000080263.46164.97.; Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am. 1995; 9 (4): 901–923. http://europepmc.org/abstract/med/8747772. Accessed November 26, 2015.; Mañez R, Breinig MC, Linden P et al. Posttransplant Lymphoproliferative Disease in Primary Epstein–Barr Virus Infection after Liver Transplantation: The Role of Cytomegalovirus Disease. J Infect Dis. 1997; 176 (6): 1462–1467. doi:10.1086/514142.; Cobbs CS, Harkins L, Samanta M et al. Human Cytomegalovirus Infection and Expression in Human Malignant Glioma. Cancer Res. 2002; 62 (12): 3347–3350. http://cancerres.aacrjournals.org/content/62/12/3347.short.Accessed November 26, 2015.; Smith BA, Shuchman M. Problem of nonadherence in chronically ill adolescents: strategies for assessment and intervention. Curr Opin Pediatr. 2005; 17 (5): 613–618. doi:10.1097/01.mop.0000176443.26872.6e.; Danziger-Isakov L, Bucavalas J. Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers. Am J Transplant. 2014; 14 (8): 1908–1911. doi:10.1111/ajt.12755.; Bedel AN, Hemmelgarn TS, Kohli R. Retrospective review of the incidence of cytomegalovirus infection and diseaes post liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir versus oral valganciclovir. Liver Transpl. 2012; 18 (3): 347–354. doi:10.1002/lt.22471.Retrospective.; Müller V, Perrakis A, Meyer J et al. The value of preemptive therapy for cytomegalovirus after liver transplantation. Transplant Proc. 2012; 44 (5): 1357–1361. doi:10.1016/j.transproceed.2011.11.067.; Lee S, Razonable R. Current concepts on cytomegalovirus infection after liver transplantation. World j hepatol. 2010; 2 (9): 325–336. doi:10.4254/wjh.v2.i9.325.; Krampe K, Briem-Richter A, Fischer L, Nashan B, Ganschow R. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen. Pediatr Transplant. 2010; 14 (3): 67–71. doi:10.1111/j.1399-3046.2008.01120.x.; Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet (London, England). 2005; 365 (9477): 2105–2115. doi:10.1016/S0140-6736(05)66553-1.; Sester U, Gärtner BC, Wilkens H et al. Differences in CMV-specifi c T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 2005; 5 (6): 1483–1489. doi:10.1111/j.1600-6143.2005.00871.x.; Cope AV, Sabin C, Burroughs A, Rolles K, Griffi ths PD, Emery VC. Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor–Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation. J Infect Dis. 1997; 176 (6): 1484–1490. doi:10.1086/514145.; Razonable A. Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Curr Opin Organ Transplant. 2008; 2 (1): 610–617. http://www.turkiyeklinikleri.com/article/en-cytomegalovirus-disease-in-solid-organ-transplantrecipients-advances-lead-to-new-challenges-and-opportunities-56994.html. Accessed November 26, 2015.; Falagas ME. Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients. Ann Intern Med. 1997; 126 (4): 275. doi:10.7326/0003-4819-126-4-199702150-00003.; Falagas ME, Paya C, Ruthazer R et al. Signifi cance of Cytomegalovirus for Long-Term Survival after Orthotopic Liver Transplantation. Transplantation. 1998; 66 (8): 1020–1028. doi:10.1097/00007890-199810270-00010.; Seehofer D, Rayes N, Neumann UP et al. Changing impact of cytomegalovirus in liver transplantation – a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis. Transpl Int. 2005; 18 (8): 941–948. doi:10.1111/j.1432-2277.2005.00162.x.; de Otero J, Gavalda J, Murio E et al. Cytomegalovirus Disease as a Risk Factor for Graft Loss and Death After Orthotopic Liver Transplantation. Clin Infect Dis. 1998; 26 (4): 865–870. doi:10.1086/513949.; Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the effi cacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005; 143 (12): 870–880. http://www.ncbi.nlm.nih.gov/pubmed/16365468. Accessed November 24, 2015.; Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008; 14 (31): 4849–4860. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2739936&tool=pmcentrez&rendertype=abstract. Accessed November 24, 2015.; Paya CV, Wilson JA, Espy MJ et al. Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, PlaceboControlled Trial. J Infect Dis. 2002; 185 (7): 854–860. doi:10.1086/339449.; Slifkin M, Ruthazer R, Freeman R et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl. 2005; 11 (12): 1597–1602. doi:10.1002/lt.20523.; Falagas ME, Snydman DR, Ruthazer R et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant. 1997; 11 (5 Pt 1): 432–437. http://europepmc.org/abstract/med/9361936. Accessed November 26, 2015.; Campbell AL, Herold BC. Strategies for the prevention of cytomegalovirus infection and disease in pediatric liver transplantation recipients. Pediatr Transplant. 2004; 8 (6): 619–627. doi:10.1111/j.1399-3046.2004.00242.x.; Mumtaz K, Faisal N, Husain S, Morillo A, Renner EL, Shah PS. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2015; 15 (2): 472–481. doi:10.1111/ajt.13044.; Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl. 2006; 12 (1): 112–116. doi:10.1002/lt.20562.; Strippoli GFM, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation. 2006; 81 (2): 139–145. doi:10.1097/01.tp.0000183970.71366.da.; Kotton CN, Kumar D, Caliendo AM et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013; 96 (4): 333–360. doi:10.1097/TP.0b013e31829df29d.; Wloch MK, Smith LR, Boutsaboualoy S et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis. 2008; 197 (12): 1634–1642. doi:10.1086/588385.; Modlin JF, Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004; 39 (2): 233–239. doi:10.1086/421999.; Togashi J, Sugawara Y, Hashimoto M et al. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: A randomized trial. Biosci Trends. 2011; 5 (5): 217–222. doi:10.5582/bst.2011.v5.5.217.; Åsberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant. 2014; 18 (1): 103–111. doi:10.1111/petr.12179.; Pescovitz MD, Ettenger RB, Strife CF et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis. 2010; 12 (3): 195–203. doi:10.1111/j.1399-3062.2009.00478.x.; Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular fi ltration ratein full-term infants during the fi rst year of life. J Pediatr. 1984; 104 (6): 849–854. doi:10.1016/S0022-3476(84)80479-5.; Villeneuve D, Brothers A, Harvey E et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant. 2013; 17 (1): 80–85. doi:10.1111/petr.12030.; https://journal.transpl.ru/vtio/article/view/621

الاتاحة: https://journal.transpl.ru/vtio/article/view/621
https://doi.org/10.15825/1995-1191-2016-1-67-77

المؤلفون: S. V. Gautier, T. A. Dzhanbekov, D. G. Akhaladze, С. В. Готье, Т. А. Джанбеков, Д. Г. Ахаладзе

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 17, № 4 (2015); 77-89 ; Вестник трансплантологии и искусственных органов; Том 17, № 4 (2015); 77-89 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2015-4

مصطلحات موضوعية: предоперационное обследование донора и реципиента, intra-abdominal hypertension, preoperative evaluation of donor and recipient, интраабдоминальная гипертензия

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/594/510; Starzl TE, Groth CG, Brettschneidez L. Orthotopic transplantation of the human liver. Amer. Surg. 1968; 168: 392–415.; Bismuth H, Houssin D. Redused-size orthotopic liver graft in hepatic transplantation in children. Surgery. 1984; 95: 365–267.; Broelsch CE, Emond JC, Whitington PF, Thistlethwaite JR, Baker L, Lichtor JL. Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg. 1990; 212: 368–375; discussion 375–377.; Шумаков ВИ, Гальперин ЭИ, Неклюдова ЕА и др. Пересадка левой доли печени в эксперименте и клинике. Хирургия. 1978; 6: 22–29. Shumakov VI, Gal'perin JeI, Nekljudova EA i dr. Peresadka levoj doli pecheni v jeksperimente i klinike. Hirurgija. 1978; 6: 22–29.; Шумаков ВИ, Гальперин ЭИ, Неклюдова ЕА. Трансплантация печени. 1981: 205–207. Shumakov VI, Gal'perin JeI, Nekljudova EA. Transplantacija pecheni. 1981: 205–207.; Шумаков ВИ, Гальперин ЭИ, Неклюдова ЕА. Трансплантация печени / АМН СССР. Медицина. 1981: 200–203. Shumakov VI, Gal'perin JeI, Nekljudova EA. Transplantacija pecheni / AMN SSSR. Medicina. 1981: 200–203.; Готье СВ, Баранов АА, Каганов БС, Зайнудинов ЗМ. Трансплантация печени у детей: состояние проблемы. Рос. педиат. журн. 2003; 1: 39–44. Got'e SV, Baranov AA, Kaganov BS, Zajnudinov ZM. Transplantacija pecheni u detej: sostojanie problemy. Ros. pediat. zhurn. 2003; 1: 39–44.; Готье СВ, Константинов БА, Цирульникова ОМ. Трансплантация печени. 2008: 120–125. Got'e SV, Konstantinov BA, Cirul'nikova OM. Transplantacija pecheni. 2008: 120–125.; Исхаги СХ и др. 30-летие Единого координационного донорского центра. Клиническая и экспериментальная хирургия – журнал им. акад. Б.В. Петровского. 2014; 2: 71–76. Ishagi SH i dr. 30-letie Edinogo koordinacionnogo donorskogo centra. Klinicheskaja i jeksperimental'naya hirurgija – zhurnal im. akad. B.V. Petrovskogo. 2014; 2: 71–76.; Darwish A, Bourdeaux C, Kader H et al. Pediatric liver transplantation using left hepatic segments from living related donors: Surgical experience in 100 recipients at Saint-Luc University Clinics. Pediatr Transplant. 2006; 10: 345–353.; Ho P, Chung Y, Ching S et al. Recipient body size does not matter in pediatric liver transplantation. J Pediatr Surg. 2014; 49 (12): 1734–1737.; Iglesias J, López J, Ortega J, Roqueta J, Asensio M, Margarit C. Liver transplantation in infants weighing under 7 kilograms: Management and outcome of PICU. Pediatr Transplant. 2004; 8: 228–232.; Lucianetti А, Guizzetti M, Bertani А et al. Liver transplantation in children weighting less than 6 kg: The bergamo experience. Transplant Proc. 2005; 37: 1143– 1145.; Noujaim HM, Mayer DА, Buckles JА et al. Techniques for and outcome of liver transplantation in neonates and infants weighing up to 5 kilograms. J Pediatr Surg. 2002; 37: 159–164.; Гельфанд БР, Проценко ДН, Подачин ПВ, Гельфанд ЕБ, Чубченко СВ. Синдром интраабдоминальной гипертензии. 2008. Gel'fand BR, Procenko DN, Podachin PV, Gel'fand EB, Chubchenko SV. Sindrom intraabdominal'noj gipertenzii. 2008.; Torquato JA, Lucato JJ, Antunes T, Barbas CV. Interaction between intra-abdominal pressure and positive-end expiratory pressure. Clinics (Sao Paulo). 2009; 64 (2): 105–112.; Cheatham ML, Ivatury RR, Malbrain ML, Sugrue M. Options and challenges for the future. Ivatury R, Cheatham M, Malbrain M, Sugrue M (eds) Abdominal Compartment Syndrome. Landes Bioscience, Georgetown. 2006: 295–300.; Cheatham ML, White MW, Sagraves SG, Johnson JL, Block EF. Abdominal perfusion pressure: a superior parameter in the assessment of intra-abdominal hypertension. J Trauma. 2000; 49: 621–626.; Deeren D, Dits H, Malbrain MLNG. Correlation between intra-abdominal and intracranial pressure in nontraumatic brain injury. Intensive Care Med. 2005; 31: 1577–1581.; Malbrain ML. Abdominal perfusion pressure as a prognostic marker in intra-abdominal hypertension. Vincent JL (eds). Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag, Heidelberg. 2002: 792–814.; Ravishankar N, Hunter J. Measurement of intra-abdominal pressure in intensive care units in the United Kingdom: a national postal questionnaire study. Br J Anaesth. 2005; 94: 763–766.; Tiwari A, Myint F, Hamilton G. Recognition and management of abdominal compartment syndrome in the United Kingdom. Intensive Care Med. 2006; 32: 906–909.; Sugrue M, Hallal A, D’Amours S. Intra-abdominal pressure hypertension and the kidney. Ivatury R, Cheatham M, Malbrain M, Sugrue M (eds) Abdominal Compartment Syndrome. Landes Bioscience, Georgetown. 2006: 119–128.; Malbrain ML. Different techniques to measure intra-abdominal pressure (IAP): time for a critical re-appraisal. Intensive Care Med. 2004; 30: 357–371.; Biancofiore G, Bindi ML, Boldrini A et al. Intraabdominal pressure in liver transplant recipients: Incidence and clinical significance. Transplant Proc. 2004; 36: 547– 549.; Malbrain M, De laet IE. Intra-abdominal hypertension: evolving concepts. Clin Chest Med. 2009; 30 (1): 45–70.; Hatsuno T, Kaneko T, Ito S, Nakao A. Sonographic measurement of the volume of the left lateral segment of the liver. J Clin Ultrasound. 2002; 30 (3): 117–122.; Kasahara M, Fukuda A, Yokoyama S et al. Living donor liver transplantation with hyperreduced left lateral segments. J Pediatr Surg. 2008; 43: 1575–1578.; Sakamoto S, Kanazawa H, Shigeta T. Technical considerations of living donor hepatectomy of segment 2 grafts for infants. Surgery: 1–6.; Arnon R, Annunziato R, Miloh T et al. Liver transplantation in children weighing 5 kg or less: Analysis of the UNOS database. Pediatr Transplant. 2011; 15 (March 2002): 650–658.; Dunn SP, Weintraub W, Vinocur CD, Billmire DF, Falkenstein K. Is age less than 1 year a high-risk category for orthotopic liver transplantation? J Pediatr Surg. 1993; 28 (8): 1048–1050.; Noda T, Todani T, Watanabe Y, Yamamoto S. Liver volume in children measured by computed tomography Pediatr Radiol. 1997; 27: 250–252.; Urahashi T, Mizuta K, Sanada Y, Wakiya T, Yasuda Y, Kawarasaki H. Liver graft volumetric changes after living donor liver transplantation with segment 2 graft for small infants. Pediatr Transplant. 2012; 16: 783–787.; Urata K, Kawasaki S, Matsunami H et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995; 21: 1317–1321.; Yoshizumi T, Taketomi А, Kayashima H et al. Estimation of Standard Liver Volume for Japanese Adults. Transplant Proc. 2008; 40: 1456–1460.; Kiuchi T, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. 1999.; Herden U, Wischhusen F, Heinemann A et al. A formula to calculate the standard liver volume in children and its application in pediatric liver transplantation. Transpl Int. 2013; 26: 1217–1224.; Gelas T, Df M, Boillot O et al. Can donor liver left lateral sector weight be predicted from anthropometric variables? 2012: 239–243.; Enne M, Pacheco-Moreira L, Balbi E, Cerqueira A, Santalucia G, Martinho JM. Liver transplantation with monosegments. Technical aspects and outcome: A metaanalysis. Liver Transplant. 2005; 11 (5): 564–569.; Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided sub-segmentectomy. Surg Gynecol Obstet. 1985; 161: 346–350.; Mizuta K, Yasuda Y, Egami S et al. Living donor liver transplantation for neonates using segment 2 monosubsegment graft. Am J Transplant. 2010; 10: 2547–2552.; Meyer WW, Lind J. The ductus venosus and the mechanism of its closure. Arch Dis Child. 1966; 41: 597–605.; Attia MS, Stringer MD, McClean P, Prasad KR. The reduced left lateral segment in pediatric liver transplantation: An alternative to the monosegment graft. Pediatric Transplant. 2008; 12 (January 2002): 696–700.; Houssin D, Soubrane O, Boillot O et al. Orthotopic liver transplantation with a reduced-size graft: An ideal compromise in pediatrics? Surgery. 1992: 111: 532– 542.; Perkins JD. Are we reporting the same thing? Comments. Liver Transplant. 2007; 13: 465–466.; Reding R, Dhawan A, Esquivel CO. Grafts too big or too small: Business as usual in pediatric liver transplantation. Pediatr Transplant. 2012; 16 (6): 212–213.; Rogiers X, Broelsch CE. Reduced-Size Hepatic. 1995: 507–512.; Shirouzu Y, Ohya Y, Hayashida S, Yoshii T, Asonuma K, Inomata Y. Reduction of left-lateral segment from living donors for liver transplantation in infants weighing less than 7 kg: Technical aspects and outcome. Pediatr Transplant. 2010; 14: 709–714.; Tiao GM, Alonso M, Bezerra J et al. Liver transplantation in children younger than 1 year-the Cincinnati experience. J Pediatr Surg. 2005; 40: 268–273.; Shehata MR, Yagi S, Okamura Y et al. Pediatric liver transplantation using reduced and hyper-reduced left lateral segment grafts: A 10-year single-center experience. Am J Transplant. 2012; 12: 3406–3413.; Ardiles V, Ciardullo M, D’Agostino D et al. Transplantation with hyper-reduced liver grafts in children under 10 kg of weight. Langenbeck’s Arch Surg. 2013; 398: 79–85.; Zenitani M, Ueno T, Nara K et al. A case of pediatric live-donor liver transplantation with a left lateral segment reduction by a linear stapler after reperfusion. 2014: 197–199.; Schulze M, Dresske B, Deinzer J et al. Implications for the usage of the left lateral liver graft for infants ≤10 kg, irrespective of a large-for-size situation – Are monosegmental grafts redundant? Transpl Int. 2011; 24: 797–804.; De Ville De Goyet J, Struye De Swielande Y, Reding R, Sokal EM, Otte JB. Delayed primary closure of the abdominal wall after cadaveric and living related donor liver graft transplantation in children: A safe and useful technique. Transpl Int. 1998; 11: 117–122.; Karpelowsky JS, Thomas G, Shun A. Definitive abdominal wall closure using a porcine intestinal sumucosa biodegradable membrane in pediatric transplantation. Pediatr Transplant. 2009; 13 (5): 285–289.; Lafosse A, De Magnee C, Brunati A et al. Combination of tissue expansion and porcine mesh for secondary abdominal wall closure after pediatric liver transplantation. Pediatr Transplant. 2012; 16: 1–3.; Pulido JA. Porcine acellular dermal matrix for delayed abdominal wall closure after pediatric liver transplantation. 2014: 594–598.; Gautier S, Akhaladze D, Tsirulnikova O, Dzhanbekov T et al. «Large-for-size» in left lateral section liver graft for infants. Pediatric transplantation / Special issue: IPTA 8th Congress on Pediatric Transplantation. 19; S1: 130.; https://journal.transpl.ru/vtio/article/view/594

الاتاحة: https://journal.transpl.ru/vtio/article/view/594
https://doi.org/10.15825/1995-1191-2015-4-77-89

المؤلفون: S. V. Gautier, S. V. Golovinsky, V. N. Poptsov, O. M. Tsiroulnikova, S. A. Krasovsky, A. A. Mitrokhin, M. M. Vodneva, P. V. Sarygin, D. G. Akhaladze, E. А. Spirina, С. В. Готье, С. В. Головинский, В. Н. Попцов, О. М. Цирульникова, С. А. Красовский, А. А. Митрохин, М. М. Воднева, П. В. Сарыгин, Д. Г. Ахаладзе, Е. А. Спирина

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 18, № 2 (2016); 110-116 ; Вестник трансплантологии и искусственных органов; Том 18, № 2 (2016); 110-116 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2016-2

مصطلحات موضوعية: гипербарическая оксигенация (ГБО), Burkholderia cepacia, lung transplantation, hyperbaric oxygenation (HBO), трансплантация легких

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/645/546; Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report-2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015; 34 (10): 1264– 1277.; Stephenson AL, Sykes J, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA et al. Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. J Heart Lung Transplant. 2015; 34 (9); 1139–1145.; Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S et al. A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015; 34 (1): 1–15.; Olland A, Falcoz P-E, Kessler R, Massard G. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? Interact Cardiovasc Thorac Surg. 2011; 13 (6): 631–634.; O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009; 373 (9678): 1891–1904.; Красовский СА, Амелина ЕЛ, Черняк АВ, Никонова ВС, Воронкова АЮ, Каширская НЮ и др. Муковисцидоз взрослых: увеличение выживаемости больных в Москве и Московской области. Терапевтический архив. 2012; 84 (3): 54–58. Krasovsky SA, Amelina EL, Chernyak AV, Nikonova VS, Voronkova AYu, Kashirskaya NYu et al. Adult-onset mucoviscidosis: longer survival of patients in Moscow and Moscow region. Terapevticheskiy arkhiv. 2012; 84 (3): 54–58.; Ramos KJ, Quon BS, Psoter KJ, Lease ED, Mayer-hamblett N, Aitken ML et al. Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States. J Cyst Fibros. 2015; 1–8.; Mall J. Stuart MAE, editor. Cystic Fibrosis. European Respiratory Society. 2014: 332.; Семыкин СЮ, Постников СС, Поликарпова СВ, Нажимов ВП, Чернуха МЮ, Авакян ЛВ. Burcholderia сepacia – новая угроза для больных муковисцидозом. Детская больница. 2013; 2: 52–55. Semykin SYu, Postnikov SS, Polikarpova SV, Nazhimov VP, Chernukha MYu, Avakyan LV. Burcholderia cepacia – new threat for the patients with cystic fibrosis. Detskaya bol’nitsa. 2013; 2: 52–55.; Weidmann A, Webb AK, Dodd ME, Jones AM. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J Cyst Fibros. 2008; 7 (5): 409–411.; Williams SG, Ashworth F, McAlweenie A, Poole S, Hodson ME, Westaby D. Percutaneous endoscopic gastrostomy feeding in patients with cystic. Gut. 1999; 44 (1): 87–90.; Dosanjh A. A review of nutritional problems and the cystic fibrosis lung transplant patient. Pediatr Transplant. 2002; 6 (6): 388–391.; De Soyza A, Meachery G, Hester KLM, Nicholson A, Parry G, Tocewicz K et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant. 2010; 29 (12): 1395–1404.; Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2009; 179 (3): 257–258.; Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008; 63 (8): 732– 737.; Гипербарическая медицина, практическое руководство (под редакцией Д. Матьё). М.: Бином, 2009: 720 (Перевод с англ.). Handbook on Hyperbaric Medicine (edit by D. Mathieu). M.: Binom, 2009: 720 (Translated from English).; https://journal.transpl.ru/vtio/article/view/645

الاتاحة: https://journal.transpl.ru/vtio/article/view/645
https://doi.org/10.15825/1995-1191-2016-2-110-116

المؤلفون: V. I. Sevastianov, G. A. Dukhina, A. M. Grigoriev, N. V. Perova, L. A. Kirsanova, N. N. Skaletskiy, D. G. Akhaladze, S. V. Gautier, В. И. Севастьянов, Г. А. Духина, А. М. Григорьев, Н. В. Перова, Л. А. Кирсанова, Н. Н. Скалецкий, Д. Г. Ахаладзе, С. В. Готье

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 17, № 1 (2015); 86-96 ; Вестник трансплантологии и искусственных органов; Том 17, № 1 (2015); 86-96 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2015-1

مصطلحات موضوعية: жировая ткань, osteoarthrosis, hyaline cartilage, cartilaginous tissue, cell-engineered construct, biopolymer matrix, mesenchymal stromal cells, adipose tissue, экспериментальная модель, гиалиновый хрящ, клеточно-инженерная конструкция, биополимерный матрикс, мезенхимальные стромальные клетки

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/500/437; Atala A, Lanza R, Thompson J, Nerem R. Principles of regenerative medicine. Academic Press is an imprint of Elsevier, First edition; 2008.; Ревматология. Национальное руководство. Под ред. Насонова ЕЛ, Насоновой ВА. Москва: ГЭОТАР-Медиа, 2010: 720. Rheumatology. National handbook. Eds. Nasonov EL, Nasonova VA. GEOTAR-Media: Moscow, 2010.; Melero-Martin JM, Al-Rubeai M. In vitro expansion of chondrocytes. Topics in Tissue Engineering. 2007; 3: 37.; Мазуров ВИ. Болезни суставов. СПб.: СпецЛит, 2008: 27–31. Mazurov VI. Joint disease. SPb: SpetsLit, 2008: 27–31.; Деев РВ. Анализ рынка клеточных препаратов для коррекции патологии скелетных тканей. Клеточная трансплантология и тканевая инженерия. 2006; 2 (4): 78–83. Deev RV. Market analysis of cell preparations for correction of the pathology of the skeletal tissues. Cell Transplantology and Tissue Engineering. 2006; 2 (4): 78–83.; Jones DG., Peterson L. Autologous chondrocyte implantation. In the book: Cartilage repair strategies. Ed. by Williams RJ. Humana Press, Totowa, New Jersey. 2007: 137–166.; Сургученко ВА. Матриксы для тканевой инженерии и гибридных органов. Биосовместимые материалы (учебное пособие). Под ред. Севастьянова ВИ, Кирпичникова МП. Москва: МИА, 2011. Ч. II; гл. 1: 199–228. Surguchenko VA. The matrices for tissue engineering and hybrid organs. Biocompatible materials (textbook). Ed. by: Sevastianov VI, Kirpichnikov MP. Moscow: MIA, 2011; 2 (1): 199–228.; http://www.genzyme.com; http://www.osiristx.com; http://www.tigenix.com; http://www.biotissue.de; http://www.arthro-kinetics.com; http://www.anikatherapeutics.com; http://www.codon.de; http://www.aci.dk; Husing B, Buhrlen B, Gaisser S. Human Tissue Engineered Products – Today's Markets and Future Prospects, Annex of the Final Report for Work Package 1: Analysis of the actual market situation – Mapping of industry and products, Fraunhofer Institute for Systems and Innovation Research, Karlsruhe, Germany. 2003: 54.; http://www.tetec-gmbh.de; Chung C, Burdick JA. Engineering Cartilage Tissue. Adv Drug Deliv Rev. 2008; 60 (2): 243–262.; Redman SN, Oldfield SF, Archer CW. Current strategies for articular cartilage repair, European Cells and Materials. 2005; 9: 23–32.; Danišovič Ľ, Lesný P, Havlas V, Teyssler P, Syrová Z, Kopáni M et al. Chondrogenic differentiation of human bone marrow and adipose tissue-derived mesenchymal stem cells. Applied Biomedicine. 2007; 5: 139–150.; Севастьянов ВИ, Перова НВ, Немец ЕА, Сургученко ВА, Пономарева АС. Примеры экспериментальноклинического применения биосовместимых материалов в регенеративной медицине. Биосовместимые материалы (учебное пособие). Под ред. Севастьянова ВИ, Кирпичникова МП. М.: МИА, 2011. Ч. II, гл. 3: 237–252. Sevastianov VI, Perova NV, Nemets EA, Surguchenko VA, Ponomareva AS. Biocompatible materials (textbook). Ed. by: Sevastianov VI, Kirpichnikov MP. Moscow: MIA. 2011; 2 (3): 237–252.; Пономарева АС, Сургученко ВА, Богданова НБ., Можейко НП., Севастьянов ВИ. Исследование дифференцировочного потенциала мезенхимальных стромальных клеток из жировой ткани человека. Вестник Саратовского государственного технического университета. 2011; 1 (53): 215–220. Ponomareva AS, Surguchenko VA, Bogdanova NB, Mozhejko NP, Sevastianov VI. The study differencirovannoe potential of mesenchymal stromal cells from human fat tissue. Vestnik Saratovskogo gosudarstvennogo tehnicheskogo universiteta. 2011; 1 (53): 215–220.; Zuk PA, Zhu M, Mizuno H, Huang J, Futrell W, Katz AJ et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue engineering. 2001; 17 (1): 211–228.; Севастьянов ВИ, Духина ГА, Пономарева АС, Кирсанова ЛА, Перова НВ, Скалецкий НН. Биомедицинский клеточный материал для регенерации суставного хряща: биосовместимые и гистоморфологические свойства (экспериментальная модель подкожной имплантации). Перспективные материалы. 2014; 10: 28–39. Sevastianov VI, Dukhina GA, Ponomareva AS, Kirsanova LA, Perova NV, Skaletskiy NN. A biomedical cell product for the regeneration of articular cartilage: Biocompatible and histomorphological properties (An experimental model of subcutaneous implantation). Perspective materials. 2014; 10: 28–39.; Surguchenko VA, Ponomareva AS, Kirsanova LA, Skaleckij NN, Sevastianov VI. The cell-engineered construct of cartilage on the basis of biopolymer hydrogel matrix and human adipose tissue-derived mesenchymal stromal cells (in vitro study). J. Biomed. Mater. Research. 2015; 103A (2): 463–470.; Егорова ВА, Пономарева АС, Богданова НБ, Абрамов ВЮ, Севастьянов ВИ. Характеристика фенотипа МСК из жировой ткани человека методом проточной цитометрии. Технологии живых систем. 2009; 6 (5): 40–46. Egorova VA, Ponomareva AS, Bogdanova NB, Abramov VYu, Sevastianov VI. Characteristic phenotype MSC from the fatty tissue of humans by flow cytometry. Technologies of living systems.2009; 6 (5): 40–46.; Макушин ВД, Степанов МА, Ступина ТА. Экспериментальное моделирование остеоартроза коленного сустава у собак. Биомедицина. 2012; 3: 108–115. Makushin VD, Stepanov MA, Stupina TA. Experimental modeling of knee joint osteoarthrosis in dogs. Biomedicine. 2012; 3: 108–115.; Vallon R, Freuler F. et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and transcription of matrix metalloproteinases. Immunology. 2001; 166: 2801–2807.; Шиманский ВА, Кушнир ВА, Фролов ВИ, Крашенинников МЕ, Баранова ОВ, Онищенко НА. Применение аутологичных клеток костного мозга для торможения разрушения структуры хряща при остеоартрозе коленных суставов. Биологические резервы клеток костного мозга и коррекция органных дисфункций. Под ред. Шумакова ВИ, Онищенко НА. М.: ЛАВР, 2009; гл. 10: 213–224. Shimansky VA, Kushnir VA, Frolov VI, Krasheninnikov IU, Baranova S, Onishchenko NA. The use of autologous bone marrow cells for inhibition of the destruction of the structure of cartilage in osteoarthritis of the knee. Biological reserves bone marrow cells and correction of organ dysfunction. Ed. Shumakov VI, Onishchenko NA. M.: LAVR, 2009; Ch. 10: 213–224.; Fisher SA, Tam RY, Shoichet MS. Tissue mimetics: engineered hydrogel matrices provide biomimetic environments for cell growth. Tissue Engineering. 2014; Part A, 20 (5, 6): 895–898.; Севастьянов ВИ, Перова НВ, Сайковский РС, Соловьева ИВ. Применение инъекционных форм биополимерных гетерогенных гидрогелей при дегенеративно-дистрофических поражениях суставов: Практическое пособие для врачей. М.: Триада, 2012: 27. Sevastianov VI, Perova NV, Sajkovskij RS, Solov'eva IV. The use of injectable biopolymer heterogeneous hydrogels with degenerative-dystrophic lesions of the joints. Practical manual for doctors. M.: Triada; 2012.; Сайковский РС, Савенкова НА, Аверьянов АВ, Лисица АВ. Эффективность применения препарата Сферогель для лечения гонартроза. Клиническая практика. 2013; 3: 4–10. Saykovskiy RS, Savenkova NA, Averyanov AV, Lisitsa AV. The effectiveness of Spherogel in the treatment of knee osteoarthritis. Klinicheckaya praktika. 2013; 3: 4–10.; https://journal.transpl.ru/vtio/article/view/500

الاتاحة: https://journal.transpl.ru/vtio/article/view/500
https://doi.org/10.15825/1995-1191-2015-1-86-96

المؤلفون: S. V. Gautier, O. M. Tsiroulnikova, D. G. Akhaladze, A. R. Monakhov, Kh. M. Khizroev, I. E. Tsiroulnikova, S. V. Meshcheryakov, T. A. Dzhanbekov, G. A. Saranov, N. N. Abramova, С. В. Готье, О. М. Цирульникова, Д. Г. Ахаладзе, А. Р. Монахов, Х. М. Хизроев, И. Е. Цирульникова, С. В. Мещеряков, Т. А. Джанбеков, Г. А. Саранов, Н. Н. Абрамова

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 16, № 4 (2014); 106-110 ; Вестник трансплантологии и искусственных органов; Том 16, № 4 (2014); 106-110 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2014-4

مصطلحات موضوعية: трансплантация левой доли печени, situs inversus, left lobe liver transplantation, транспозиция внутренних органов

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/480/420; Готье СВ, Ахаладзе ДГ. Технические аспекты сосудистой реконструкции при трансплантации левого латерального сектора печени взрослого донора в педиатрической практике. Вестник трансплантологии и искусственных органов. 2012; XIV, No 1: 86–94. Gautier SV, Akhaladze DG. Tekhnicheskie aspekty sosudistoĭ rekonstruktsii pri transplantatsii levogo lateral'nogo sektora pecheni vzroslogo donora v pediatricheskoĭ praktike. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2012; XIV, No 1: 86–94.; Готье СВ, Константинов БА, Ци рульникова ОМ. Трансплантация печени. 2008; 73–74. Gautier SV, Konstantinov BA, Tsirul'nikova OM. Transplantatsiya pecheni. 2008; 73–74.; Цирульникова ИЕ, Шевченко ОП. AB0-несовместимая трансплантация печени у детей : анализ мирового опыта. Вестник трансплантологии и искусственных органов. 2012; XIV, No 4: 115–123. Tsirul'nikova IE, Shevchenko OP. AB0-nesovmestimaya transplantatsiya pecheni u deteĭ : analiz mirovogo opyta. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2012; XIV, No 4: 115–123.; Al Jumaily M, Hoche F. Laparoscopic cholecystectomy in situs inversus totalis: is it safe? Journal of Laparoendoscopic and Advanced Surgical Techniques: Part A. 2001; 11 (4): 229–231.; Asfar S, Ozcay N, Grant D, Wall W. Transplantation of the liver from a donor with complete situs inversus and dextrocardia. Transplantation. 1995; 59: 442–444.; Braun F, Rodeck B, Lorf T, Canelo R, Wietzke P, Hartmann H et al. Situs inversus of donor or recipient in liver transplantation. TransplInt. 1998; 11: 212–215.; Cheikhelard A, De Lagausie P, Garel C, Maintenant J, Vuillard E, Blot P, Aigrain Y. Situs inversus and bowel malrotation: Contribution of prenatal diagnosis and laparoscopy. J PediatrSurg. 2000; 35: 1217–1219.; Chun JM, Jung GO, Choi GS et al. Living donor liver transplantation using a graft from a donor with situs inversus totalis. Liver Transplantation. 2009; 15 (6): 666– 669.; Cleveland M. Situs inversus viscerum an anatomic study. Arch Surg. 1926; 13 (3): 343–368.; Dou J, Yang T, Cao J.-L, Gao Q.-J, Su Y.-L, Zhu Z.-J. Classical orthotopic liver transplantation from a donor with situs inversus totalis using slight rotation of the liver graft. Chinese Medical Journal. 2010; 123 (10): 1353–1355.; Herrera LA, Castillo J, Martino E, Rabanal JM, Fleitas MG. Orthotopic liver transplantation from a donor with abdominal situs inversus. Transplantation. 1996; 62: 133–135.; Mayo CW, Rice RG. Situs inversus totalis: a statistical review of data on seventy-six cases with special reference to disease of the biliary tract. Arch Surg. 1949; 58: 724–730.; Mittal V, Shah A. Situs Inversus Totalis: The Association of Kartagener’s Syndrome With Diffuse Bronchiolitis nd Azoospermia. Arch Bronconeumol. 2012; 48 (5): 179–182.; Polak WG, Chudoba PJ, Patrzaled D, Szyber P. Organ donor with complete situs inversus. Case report and review of the literature. Ann Transplant. 2006; 11: 43–46.; Pomposelli JJ, DaCosta MA, McPartland K, Jenkins RL. Retroversus implantation of a liver graft: a novel approach to the deceased donor with situs inversus totalis. Am J Transplant. 2007; 7: 1869–1871.; https://journal.transpl.ru/vtio/article/view/480

الاتاحة: https://journal.transpl.ru/vtio/article/view/480
https://doi.org/10.15825/1995-1191-2014-4-106-110

المؤلفون: S. V. Gautier, O. M. Tsiroulnikova, V. N. Poptsov, E. A. Spirina, D. G. Akhaladze, S. V. Golovinskiy, С. В. Готье, О. М. Цирульникова, В. Н. Попцов, Е. А. Спирина, Д. Г. Ахаладзе, С. В. Головинский

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 17, № 2 (2015); 124-126 ; Вестник трансплантологии и искусственных органов; Том 17, № 2 (2015); 124-126 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2015-2

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/535/467; https://journal.transpl.ru/vtio/article/view/535

الاتاحة: https://journal.transpl.ru/vtio/article/view/535
https://doi.org/10.15825/1995-1191-2015-2-124-126

المؤلفون: O. P. Shevchenko, O. M. Tsirulnikova, O. E. Gichkun, L. V. Makarova, I. E. Tsirulnikova, D. G. Akhaladze, N. P. Shmerko, S. V. Gautier, О. П. Шевченко, О. М. Цирульникова, О. Е. Гичкун, Л. В. Макарова, И. Е. Цирульникова, Д. Г. Ахаладзе, Н. П. Шмерко, С. В. Готье

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 14, № 2 (2012); 15-19 ; Вестник трансплантологии и искусственных органов; Том 14, № 2 (2012); 15-19 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2012-2

مصطلحات موضوعية: трансплантация печени, pediatric liver transplantation

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/158/100; Готье С.В., Константинов Б.А., Цирульникова О.М. Трансплантация печени // М.: Медицинское инфор- мационное агентство. 2008. 296 с.; Шевченко О.П., Орлова О.В., Казаков Э.Н. и др. Кли- ническое значение растворимого лиганда CD40 у реципиентов сердца // Вестник трансплантологии и искусственных органов. 2009. No 1. С. 40–45.; Шевченко О.П., Орлова О.В., Халилулин Т.А. Имму- носупрессия, иммунная толерантность и костимуляция Т-лимфоцитов // Иммуносупрессия при транс- плантации солидных органов; под ред. С.В. Готье. М.–Тверь: Триада. 2011. С. 423–470.; Шевченко О.П., Цирульникова О.М., Олефиренко Г.А. и др. Уровень sCD30 при трансплантации печени у детей с врожденными и наследственными заболеваниями пе- чени и желчевыводящих путей // Вестник трансплан- тологии и искусственных органов. 2011. No 4. С. 37–43.; Contin C., Pitako V., Delmes Y. et al. Potential role of sCD40L in the humoral immune response impairment of uraemic patients // Immunology. 2003. Vol. 110 (1). P. 131–140.; Antoniades C., Bakogiannis C., Tousoulis D. et al. The CD40/CD40L system linking inflammation with atherothrombosis // J. Am. Coll. Cardiol. 2009. Vol. 54 (8). P. 669–677.; Gaweco A.S., Wiesner R.H., Yong S. et al. CD40L (CD154) expression in Human liver allograft during chronic ductopenic rejection // Liver transplantation and surgery. 1999. Vol. 5. No 1. P. 1–7.; Gaweco A.S., Wiesner R.H., Yong S. et al. Kupffer Cell expression of CD40L (CD154) in Human Chronic Liver; Allograft Rejection // Transplantation proceedings.; Vol. 31. P. 560–561.; Jung D.Y., Kim E.Y., Joo S.Y. et al. Prolonged survival of; islet allografts in mice treated with rosmarinic acid and; antiCD154 antibody/Exp Mol Med. 2008. Vol. 40. P. 1.; Larsen C.P., Alexander D.Z., Hollenbaugh D. et al. CD40-gp39 interactions play a critical role during al- lograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway // Transplantation.; Vol. 61. P. 4–9.; Muiesan P., Vergani D., Mieli-Vergani G. Liver transplan-; tation in children // J. Hepatol. 2007. Vol. 2. P. 340–348.; Oertelt S., Invernizzi P., Selmi C. et al. Soluble CD40L in plasma of patients with primary biliary cirrhosis // Ann; NY Acad Sci. 2005. Vol.1051. P. 205–210.; Van Kooten C., Banchereau J. CD40-CD40 ligand // J. of; Leukocyte biology. – 2000. Vol. 67. P. 2–17.; Xiuda Shen, Yue Wang, Feng Gao, Feng Ren. CD4 T Cells Promote Tissue Inflammation via CD40 Signa- ling Without De Novo Activation in a Murine Model of Liver Ischemia/Reperfusion Injury // Hepatology. 2009.; P. 1537–1546.; https://journal.transpl.ru/vtio/article/view/158

الاتاحة: https://journal.transpl.ru/vtio/article/view/158
https://doi.org/10.15825/1995-1191-2012-2-15-19

المؤلفون: S. V. Gautier, O. M. Tsiroulnikova, Y. G. Moysyuk, D. G. Akhaladze, I. E. Tsiroulnikova, O. V. Silina, Kh. M. Khizroev, A. R. Monakhov, E. V. Chekletsova, V. A. Pets, V. N. Poptsov, С. В. Готье, О. М. Цирульникова, Я. Г. Мойсюк, Д. Г. Ахаладзе, И. Е. Цирульникова, О. В. Силина, Х. М. Хизроев, А. Р. Монахов, Е. В. Чеклецова, В. А. Пец, В. Н. Попцов

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 16, № 3 (2014); 54-62 ; Вестник трансплантологии и искусственных органов; Том 16, № 3 (2014); 54-62 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2014-3

مصطلحات موضوعية: результаты трансплантации печени, left lateral section, left lobe, right lobe, whole liver transplantation, living donor of partial liver graft, liver transplantation outcomes, трансплантация левого латерального сектора, левой доли, правой доли, целой печени, родственный донор фрагмента печени

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/448/393; Готье СВ, Ахаладзе ДГ. Технические аспекты сосудистой реконструкции при трансплантации левого латерального сектора печени взрослого донора в педиатрической практике. Вестник трансплантологии и искусственных органов. 2012; XIV, № 1: 86–94. Gautier; SV, Akhaladze DG. Tekhnicheskie aspekty sosudistoĭ rekonstruktsii pri transplantatsii levogo lateral'nogo sektora pecheni vzroslogo donora v pediatricheskoĭ praktike. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2012; XIV, No1: 86–94.; Готье СВ, Константинов БА, Цирульникова ОМ. Трансплантация печени. 2008; 73–74. Gautier SV, Konstantinov BA, Tsirul'nikova OM. Transplantatsiya pecheni. 2008; 73–74. 3. Цирульникова ИЕ, Шевченко ОП. AB0-несовместимая трансплантация печени у детей: анализ мирового опыта. Вестник трансплантологии и искусственных органов. 2012; XIV, № 4: 115–123. Tsirul'nikova IE, Shevchenko OP. AB0-nesovmestimaya transplantatsiya pecheni u deteĭ : analiz mirovogo opyta. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2012; XIV, No4: 115–123.; Arnon R, Annunziato R, Schilsky M et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant. 2011; 25 (1): 52–60.; Bhatnagar V, Dhawan A, Haider C, Muiesan P, Rela M,Mowat AP et al. The incidence and management of biliary complications following liver transplantation in children. Transpl International. 1995; 8: 388–391.; Broelsch C, Neuhaus P, Burdelski M et al. Orthotopic transplantation of hepatic segments in infants with biliary atresia. Langenbecks Arch Chir (Suppl). 1984; 105.; Chui AK, Rao AR, Island ER, Lau WY. Critical graft size and functional recovery in living donor liver transplantation. Transplant Proc. 2004; 36 (8): 2277–2278.; Deen JL, Blumberg DA. Infectious disease considerations in pediatric organ transplantation. Semin. Pediatr. Surg. 1993; 2: 218–234.; Kling K, Lau H, Colombani P. Biliary complications of living related pediatric liver transplant patients. Pediatr. Transpl. 2004; 8:178–184.; Morgan G, Superina RA. Lymphoproliferative disease after paediatric liver transplantation. J. Pediatr Surg. 1994; 29:1192–1196.; Muiesan P, Vergani D, Mieli-Vergani G. Liver transplantation in children. J Hepatology. 2007; 46: 340–348.; Rubin RH. Prevention of infection in the liver transplant recipient. Liver Transplantation Surg. 1996; 2: 89–98.; Strong RW, Lunch SV, Ong TH. Successful liver transplantation from living donor to her son. N. Euql. S. Med. 1990; 322: 1505–1507.; Tsirulnikova IE, Gautier SV, Poptsov VN, Tsirulnikova OM, Shevchenko OP. AB0 incompatible pediatric liver transplantation: experience of a single center. Abstracts of the 2014 Joint International Congress of ILTS, ELITA & LICAGE. London, June 4–7, 2014. Liver Transplantation. June 2014; 20, № 6 (1): 209.; Vilca Melendez H, Vougas V, Muiesan P, Andreani P, Vergani M, Rela M et al. Bowel perforation after paediatric orthotopic liver transplantation. Transpl. Int. 1998; 11: 301–304.; Ахаладзе ДГ. Реваскуляризация трансплантата левого латерального сектора печени у детей: дис. … канд. мед. наук. 2013: 41–46. Akhaladze DG. Revaskulyarizatsiya transplantata levogo lateral'nogo sektora pecheni u deteĭ : dis. . kand. med. nauk. 2013: 41–46.; https://journal.transpl.ru/vtio/article/view/448

الاتاحة: https://journal.transpl.ru/vtio/article/view/448
https://doi.org/10.15825/1995-1191-2014-3-54-62

المؤلفون: O. P. Shevchenko, O. M. Tsirulnikova, Y. E. Lourie, A. V. Bougrov, I. E. Tsirulnikova, D. G. Akhaladze, S. V. Gautier, О. П. Шевченко, О. М. Цирульникова, Ю. Э. Лурье, А. В. Бугров, И. Е. Цирульникова, Д. Г. Ахаладзе, С. В. Готье

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 14, № 3 (2012); 31-36 ; Вестник трансплантологии и искусственных органов; Том 14, № 3 (2012); 31-36 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2012-3

مصطلحات موضوعية: трансплантация печени, liver cirrhosis, liver transplantation, цирроз печени

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/187/129; Дедов И.И., Петеркова В.А. Детская эндокриноло- гия. М.: Универсум паблишинг, 2006. 600 с.; Готье С.В., Константинов Б.А., Цирульникова О.М. и др. Трансплантация печени: Руководство для вра- чей. М.: Медицинское информационное агентство, 2008. 248 с.; Шевченко О.П., Цирульникова О.М., Бугров А.В.; Инсулиноподобный фактор роста-1 при трансплан- тации печени детям с врожденными и наследствен- ными заболеваниями гепатобилиарной системы // Вестник трансплантологии и искусственных орга- нов. 2012. No 1. С. 50–54.; Лурье Ю.Э. Инсулиноподобный фактор роста-1 // Лаборатория. 2011. No 4. С. 3–6.; Bassanello M., De Palo E.F., Lancerin F. et al. Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation:a preliminary prospective study // Liver transpl. 2004 May.Vol. 10 (5). P. 692–698. Barshes N.R., Lee T.C., Udell I.W. The pediatric end- stage liver disease (PELD) model as a predictor of sur- vival benefit and posttransplant survival in pediatric liver transplant recipients // Liver Transpl. 2006 Mar. Vol. 12 (3). P. 475–480.; Bucuvalas J.C., Horn J.A., Chernausek S.D. Resis- tance to growth hormone in children with chronic liver disease // Pediatr. Transplant. 1997 Aug. Vol. 1 (1). P. 73–79.; De Palo E.F., Bassanello M., Lancerin F. et al. GH/IGF system, cirrhosis and liver transplantation // Clin. Chim. Acta. 2001 Aug 1. Vol. 310 (1). P. 31–37.; Donaghy A.J., Delhanty P.J., Ho K.K. et al. Regulation of the growth hormone receptor / binding protein, insu- lin-like growth factor ternary complex system in human cirrhosis // J. Hepatol. 2002 Jun. Vol. 36 (6). P. 751–758. Malemud C.J. Growth hormone, VEGF and FGF: in- volvement in rheumatoid arthritis // Clin. Chim. Acta. 2007 Jan. Vol. 375 (1–2). P. 10–19.; Moller S., Becker U. Insulin-like growth factor 1 and growth hormone in chronic liver disease // Dig. Dis. 1992. Vol. 10 (4). P. 239–248.; McDiarmid S.V., Anand R., Lindblas A.S. Development of pediatric end-stage liver decease score to predict poor outcome in children awaiting liver transplantation // Transplantation. 2002. Vol. 74 (2). P. 173–181. Morrhaye G., Kermani H., Legros J-J. et al. Impact of growth hormone deficiency and growth hormone repla- cement upon thymus function in adult patients. PLoS ONE. Vol. 4 (5). E. 56688.; Picardi A., Gentilucci U.V., Zardi E.M. et al. TNF-alpha and growth hormone resistance in patients with chronic liver disease // J. Interferon Cytokine Res. 2003 May. Vol. 23 (5). P. 229–235.; Savino V., Postel-Vinay P.C., Smaniotto S. et al. The thy- mus gland: a target organ for growth hormone // Scand. J. Immunol. 2002. Vol. 55. P. 442–452.; Seehofer D., Steinmueller T., Graef K.J. et al. Pituitary function test and endocrine status in patient with cirrho- sis of the liver before and after hepatic transplantation // Ann. Transplant. 2002; Vol. 7 (2). P. 32–37.; ТРАНСПЛАНТАЦИЯ ОРГАНОВ; ; ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XIV No 3–2012; 17. Shamir R., Phillip M., Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interven- tions // Inflamm. Bowel. Dis. 2007 May. Vol. 13 (5). P. 620–628.; Tonschoff B., Blum W.F., Mehls O. Derangements of the somatotropic hormone axis in chronic renal failure // Kidney Int. Suppl. 1997 Mar. Vol. 58. S. 106–113.; Yu L.X., Liu Y.H., Shen Z.Y., Kang M.N. Prospective study of effect of recombinant human growth hormone on nut- ritional status and immune function in early postoperati- ve stage of liver transplantation // Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Jul. Vol. 19 (7). P. 390–393.; Wallace J.D., Abbott-Johnson W.J., Crawford D.H. et al. GH treatment in adults with chronic liver disease: a ran- domized, double-blind, placebo-controlled, cross-over study // J. Clin. Endocrinol. Metab. 2002 Jun. Vol. 87 (6). P. 2751–2759.; WHO Multicentre Growth Reference Study Group:WHO Child Growth Standards: Length/height-for-age, weight- for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization, 2006. 312 р. (Available at: http://www.who.int/childgrowth/standards/technical_re- port/en/); https://journal.transpl.ru/vtio/article/view/187

الاتاحة: https://journal.transpl.ru/vtio/article/view/187
https://doi.org/10.15825/1995-1191-2012-3-31-36

المؤلفون: S. V. Gautier, A. S. Ivanov, V. N. Poptsov, O. M. Tsirulnikova, S. V. Glamazda, A. S. Rodionov, A. V. Lebedeva, H. M. Hizroev, D. G. Ahaladze, M. K. Lugovskiy, I. V. Zhilkin, С. В. Готье, А. С. Иванов, В. Н. Попцов, О. М. Цирульникова, С. В. Гламазда, А. С. Родионов, А. В. Лебедева, Х. М. Хизроев, Д. Г. Ахаладзе, М. К. Луговский, И. В. Жилкин

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 16, № 1 (2014); 41-46 ; Вестник трансплантологии и искусственных органов; Том 16, № 1 (2014); 41-46 ; 2412-6160 ; 1995-1191 ; 10.15825/1995-1191-2014-1

مصطلحات موضوعية: искусственное кровообращение, дефект межпредсердной перегородки, трансплантация печени, билиарный цирроз печени

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/64/7; СПИСОК ЛИТЕРАТУРЫ / REFERENCES; Axelrod D., Koffron A., Dewolf A. et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl. 2004; 10: 1386–1390.; Barreiros A.P., Post F., Hoppe-Lotichius M. et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a sin- gle-center experience. Liver Transpl. 2010; 16: 314–323.; Eckhoff D.E., Frenette L., Sellers M.T. et al. Combined cardiac surgery and liver transplantation. Liver Transpl. 2001; 7: 60–61.; Fricker F.J., Griffith B.P., Hardesty R.L. et al. Experi- ence with hearttransplantation in children. Pediatrics. 1987; 79: 138–146.; Kniepeiss D., Iberer F., Grasser B., Schaffellner S., Tscheliessnigg K.H. Combined coronary artery bypass grafting and orthotopic livertransplantation: a case re- port. Transplant. Proc. 2003; 35: 817–818.; Manas D.M., Roberts D.R., Heaviside D.W. et al. Se- quential coronary artery bypass grafting and orthotopic liver transplantation: a case report. Clin. Transplant. 1996; 10: 320–322.; Parker B.M., Mayes J.T., Henderson J.M., Savage R.M. Combined aortic valve replacement and orthotopic liver transplantation. J. Cardiothorac. Vasc. Anesth. 2001; 15: 474–476.; Plotkin J.S., Scott V.L., Pinna A., Dobsch B.P., De- Wolf A.M., Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl. Surg. 1996; 2: 426–430.; Raichlin E., Daly R.C., Rosen C.B. et al. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009; 27: 219–225.; Starzl T.E., Bilheimer D.W., Bahnson H.T. et al. Heart- liver transplantation in a patient with familial hypercho- lesterolaemia. Lancet. 1984; 23: 1382–1383.; https://journal.transpl.ru/vtio/article/view/64

الاتاحة: https://journal.transpl.ru/vtio/article/view/64
https://doi.org/10.15825/1995-1191-2014-1-41-46